Stockwinners Market Radar for June 01, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:59 EDT World Fuel Services CEO buys 10K shares of common stock - In a regulatory filing, World Fuel Services disclosed that its CEO Michael Kasbar bought 10K shares of common stock on May 27th in a total transaction size of $314K, boosting his stake by about 1%.

19:48 EDT Eli Lilly to present data that Olumiant improved conditions in RA - The company states: "Eli Lilly (LLY) and Incyte (INCY) will present data from post-hoc analyses that suggested OLUMIANT, or baricitinib, 4 mg tablet reduced pain and duration of morning joint stiffness, and improved overall physical function at 12 weeks, among patients with moderate to severe rheumatoid arthritis, or RA, compared to HUMIRA, or adalimumab, and placebo. These results are being presented at the virtual Annual European Congress of Rheumatology, June 2-5, 2021. In a post-hoc analysis of the Phase 3 RA-BEAM study, patients treated with OLUMIANT 4 mg saw greater improvements in pain relief and physical function, as well as reduced duration of morning joint stiffness, at 12 weeks compared to HUMIRA and placebo. These differences in pain relief were not influenced by disease activity during treatment. In this analysis, improvements in fatigue with OLUMIANT 4 mg were greater than with placebo and similar to HUMIRA after 12 weeks of treatment. Safety results were consistent with the established safety profile for OLUMIANT in patients with RA."

19:03 EDT Eli Lilly says Taltz showed long-term improvement in Phase 3 study - Eli Lilly and Company will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of Taltz among patients with axial spondyloarthritis. These results are being presented at the virtual Annual European Congress of Rheumatology, June 2-5, 2021. AxSpA is recognized as a single disease entity, with two subtypes which are defined depending on the presence or absence of defined structural damage of the sacroiliac joints on plain x-ray films as per the modified New York criteria. In COAST-Y, Taltz showed consistent and sustained long-term improvements in signs and symptoms, functionality and quality of life in patients with r- and nr-axSpA. In this study, more than half of patients treated continuously with Taltz through two years achieved Assessment of SpondyloArthritis international Society 40% response. An analysis of two Phase 3 studies in r-axSpA and the long-term extension trial, found that 9 out of 10 patients treated with Taltz did not show radiographic progression for up to two years, as measured by mean change from baseline of modified Stoke Ankylosing Spondylitis Spinal Score less than2. Overall mean rates of progression were low among patients treated with Taltz. These results were similar among patients who were previously treated with anti-TNF therapy and those who had not previously been treated with a biologic.

18:23 EDT Agilent general counsel Tang sells over 13,000 common shares - In a regulatory filing, Agilent Technologies general counsel Michael Tang disclosed the sale of 13,465,275 common shares of the company on May 27 at a price of $136.154 per share.

18:08 EDT Landec sells investment in Windset Holdings for $45.1M - Landec announced that it has completed the sale of all of its equity interests in Windset Holdings to affiliates of the founding and controlling investors of Windset for a purchase price of $45.1M, which is equal to the carrying value on Landec's balance sheet as of the fiscal third quarter ended February 28, 2021.

18:05 EDT Shift CFO buys 10K shares of common stock - In a regulatory filing, Shift disclosed that its CFO Oded Shein bought 10K shares of common stock on May 27th in a total transaction size of $70K.

18:03 EDT Idexx Laboratories senior VP Turner sells 2,000 common shares - In a regulatory filing, Idexx Laboratories' senior VP Kathy Turner disclosed the sale of 2,000 common shares of the company on May 28 at a price of $558.4421 per share.

17:49 EDT RingCentral director Theis sells 2,000 class A shares - In a regulatory filing, RingCentral director Robert Theis disclosed the sale of 2,000 class A common shares of the company on May 27 at a price of $260.66 per share.

17:32 EDT Zoom Video up 3.9% after reporting better-than-expected Q1 earnings, guidance

17:21 EDT HP Enterprise falls over 2% to $15.75 after Q2 earnings and guidance

17:17 EDT Leisure Acquisition receives suspension notification from Nasdaq - Leisure Acquisition announced that on June 1, Nasdaq notified LACQ that trading in the Company's securities on Nasdaq will be suspended effective with the open of the market on Thursday, June 3 due to the Company's failure to complete an initial business combination by June 1 which date the notice stated represented the full extent of the Nasdaq Hearing Panel's discretion in this matter. The Company expects that its securities will be immediately eligible to trade on the OTC Markets system on Thursday, June 3. A

17:10 EDT Select Bancorp trading halted, news pending

17:02 EDT dMY Technology Group, Inc. III receives NYSE notice over delayed 10-Q filing - dMY Technology Group, Inc. III announced that it received a notice from the New York Stock Exchange indicating that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the Securities and Exchange Commission. The notice has no immediate effect on the listing of the Company's stock on the NYSE. The NYSE informed the company that, under the NYSE's rules, the company can regain compliance with the NYSE's continued listing requirements by filing the Q1 2021 Form 10-Q with the SEC at any time prior to November 24, 2021.

17:00 EDT Stabilis Energy acquires LNG production facility - Stabilis announced that it has completed the acquisition of an LNG production facility in Port Allen, Louisiana from HR Nu Blu Energy. Terms of the acquisition were not disclosed. The Port Allen facility is strategically located in the eastern Gulf Coast region and will support some of Stabilis' largest customers. Built in 2018, the facility has nameplate production capacity of 30,000 LNG gallons per day which increases Stabilis' total nameplate production capacity by approximately 30%. Stabilis believes that it will be able to sell all of the facility's capacity immediately with contracts from existing customers. Stabilis projects that the acquisition will be immediately accretive to earnings. Incremental annual EBITDA is projected to be $2.5M-$3M.

16:34 EDT Stealth Biotherapeutics announces elamipretide received ODD from EMA - Stealth BioTherapeutics announced that the European Medicines Agency, or EMA, has granted orphan drug designation, or ODD, for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition. ODD is granted to investigational therapies intended for the safe and effective treatment of rare diseases with an unmet medical need that affect fewer than 5 in 10,000 people in the European Union. This designation provides companies with certain benefits and incentives including clinical protocol assistance, differentiated evaluation procedures for Health Technology Assessments in certain countries, access to a centralized marketing authorization procedure valid in all EU Member States, and if approved, marketing exclusivity in the EU for 10 years.

16:32 EDT Post Holdings to acquire RTE cereal business of TreeHouse Foods for $85M - Post Holdings (POST) announced that it has acquired the ready-to-eat cereal business of TreeHouse Foods (THS) for $85M, effective June 1. The acquisition includes two facilities located in Lancaster, Ohio and Sparks, Nevada, which feature a wide range of production capabilities across batch and extruded products, a research and development facility located in Sauget, Illinois as well as inventory valued at approximately $30M. The financial results of the acquired RTE cereal business are expected to be reported in the Post Consumer Brands segment and are expected to be modestly dilutive to Post's Adjusted EBITDA for fiscal year 2021 and accretive in fiscal year 2022.

16:21 EDT Alamo Group expands board and appoints Ronald Robinson as new member - Alamo Group announced that it has expanded the membership of its Board of Directors from seven to eight members and has appointed Jeffery A. Leonard as a new member of the Board, effective June 1. As previously announced, Leonard succeeded Ronald A. Robinson as President and CEO of the Company, effective May 31.

16:17 EDT Monopar Therapeutics announces Andrew Cittadine, COO - Monopar Therapeutics announced the appointment of Andrew Cittadine, MBA, as Chief Operating Officer. In this role, Mr. Cittadine will provide leadership and oversight of Monopar's global operations and business and development strategy.

16:17 EDT Nanobiotix names Bart Van Rhijn as CFO - Nanobiotix announced the appointment of Bart Van Rhijn, MBA, as CFO and member of the company's executive board. Mr. Van Rhijn "brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for potential first-in-class radioenhancer NBTXR3 in head and neck cancer, continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations. He succeeds Philippe Mauberna, who will step down from his roles as chief financial officer and executive board member after 8 years of service to the Company. Mr. Mauberna will assume a temporary role to support the organization during transition", the company states.

16:16 EDT Motive Capital receives notice of delisting from NYSE - Motive Capital Corp. announced that it received a notice from the New York Stock Exchange on May 25, 2021 indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the Securities and Exchange Commission.

16:11 EDT Eastman Kodak says NY AG 'wrong on the facts' - Eastman Kodak Company issued the following statement in response to the New York Attorney General: "This morning the New York Attorney General filed an application in New York state court seeking investigative testimony and documents from Kodak. Prior to this filing, the Company repeatedly offered to make witnesses available and the Attorney General repeatedly declined. It is telling that she has now chosen to publicly seek this order asking for the very testimony in which she previously had no interest. Mr. Continenza was not in possession of material non-public information and, contrary to the Attorney General's allegations, his small stock purchase was pre-approved by Kodak's General Counsel during an open trading window in accordance with Kodak's insider trading policy and was subsequently found to be compliant by outside counsel in an independent investigation. Importantly, Mr. Continenza has purchased Kodak stock in virtually every open window period - and has never sold a single share. In addition to being wrong on the facts, the Attorney General's novel and highly problematic legal theory that seeks to impose liability in the absence of intent would have a chilling effect on directors and executives of every public company, who could never invest in their own companies without fear of having good-faith decisions, pre-approved by counsel, second-guessed by regulators and charged as insider trading. We are confident that the facts and the law are on our side and are prepared to present our case in court if there becomes a need to do so."

16:10 EDT HP Enterprise raises FY21 free cash flow view to $1.2B-$1.5B from $1.1B-$1.4B

16:10 EDT HP Enterprise says raising guidance to reflect momentum in demand - CEO Antonio Neri says: "Our disciplined execution on our strategic priorities is positively impacting both top and bottom line performance. We are strengthening our core compute and storage businesses, doubling down in our growth Intelligent Edge and HPC businesses and accelerating our pivot to as-a-service, while also advancing our cloud-first innovation agenda to become the edge-to-cloud platform as-a-service choice for our customers and partners. As businesses emerge from the pandemic and move beyond the immediate needs of COVID, digital transformation is at the forefront of their strategic initiatives. Our focus has been to accelerate our strategy in order to help our customers transform their businesses, optimize their applications and data across an increasingly distributed world, and be future ready, today." CFO Tarek Robbiati says: "The overall demand environment is improving, and we are seeing traction across our portfolio. We are once again raising our full-year guidance to reflect the continued momentum in the demand environment and our strong operational performance to date. This marks the third increase in our outlook since our Securities Analyst Meeting last October."

16:07 EDT Vickers Vantage Corp. I receives Nasdaq notification of non-compliance - Vickers Vantage Corp. I announced that on May 28 it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market advising the company that the company does not comply with Nasdaq's Listing Rule 5250(c)(1) for continued listing because Nasdaq has not received the company's quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2021. Nasdaq has informed the company that it has until July 26 to submit a plan to regain compliance with respect to this delinquent report. If Nasdaq approves the company's plan, it has the discretion to grant the company an extension of up to 180 calendar days from the due date of the Form 10-Q to regain compliance.

16:07 EDT Tailwind Two Acquisition gets NYSE continues listing notice - Tailwind Two acquisition announced that it received a formal notice of non-compliance from the New York Stock Exchanger elating to the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31 as required under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual. On April the staff of the Securities and Exchange Commission issued "Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies SPACs , which clarified guidance for all SPAC-related companies regarding the accounting and reporting for their warrants. The immediacy of the effective date of the new guidance set forth in the Statement has resulted in a significant number of SPACs re-evaluating the accounting treatment for their warrants with their professional advisors, including auditors and other advisors responsible for assisting SPACs in the preparation of financial statements. This, in turn, has resulted in the Company's delay in preparing and finalizing its financial statements as of and for the quarter ended March 31, 2021 and filing its Form 10-Q with the SEC by the prescribed deadline. Under NYSE rules, the Company generally has six months following receipt of the notification of non-compliance to regain compliance with the continued listing standard, subject to any extensions by NYSE.

16:04 EDT Vishay Precision acquires Diversified Technical Systems - Vishay Precision Group announced it acquired California-based Diversified Technical Systems. The transaction price is approximately $47M, subject to customary post-closing adjustments. VPG will finance the acquisition through a combination of cash on hand and third party borrowings. In 2020, DTS achieved sales of approximately $32M and an EBITDA margin in excess of 25%.

16:02 EDT Waterstone Financial declares special dividend of 50c per common share - The board of Waterstone Financial declared a special dividend of 50c per common share. The dividend will be paid on June 15 to the company's stockholders of record on June 11.

15:58 EDT NIH announces start of Phase 1/2 trial evaluating mixed COVID vaccine schedules - The National Institutes of Health has started a Phase 1/2 clinical trial in which adult volunteers who have been fully vaccinated against COVID-19 will receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens. It will include approximately 150 individuals who already have received one of the three COVID-19 vaccine regimens currently available under FDA Emergency Use Authorization in the United States: the Janssen COVID-19 vaccine, also referred to as the Johnson & Johnson (JNJ) vaccine, or Ad26.COV2-S, the Moderna (MRNA) COVID-19 vaccine, also known as mRNA-1273, and the Pfizer (PFE)-BioNTech (BNTX) COVID-19 vaccine, also known as (BNT162b2). Each vaccine group will enroll about 25 people ages 18 through 55 years and approximately 25 people age 56 years and older. Twelve to 20 weeks following their initial vaccination regimen, participants will receive a single booster dose of the Moderna COVID-19 vaccine as part of the trial. People who have not yet received an FDA authorized COVID-19 vaccine are also eligible to enroll in the trial in a separate cohort. Initially, these volunteers will receive the two-dose Moderna COVID-19 vaccine regimen and will be assigned to receive a booster dose of a vaccine about 12 to 20 weeks later. The trial has an adaptive design and may add arms as vaccines are awarded EUA and/or variant lineage vaccines become available for evaluation. "Although the vaccines currently authorized by the U.S. Food and Drug Administration offer strong protection against COVID-19, we need to prepare for the possibility of needing booster shots to counter waning immunity and to keep pace with an evolving virus. The results of this trial are intended to inform public health policy decisions on the potential use of mixed vaccine schedules should booster doses be indicated," said NIAID Director Anthony Fauci, M.D.

15:47 EDT Accenture Federal Services to acquire Novetta, terms not disclosed - Accenture Federal Services, a wholly owned subsidiary of Accenture (ACN), has entered into an agreement to acquire Novetta, an advanced analytics company serving U.S. federal organizations that are pushing the limits of what's possible with machine learning, cyber, and cloud engineering. The completion of the acquisition from The Carlyle Group (CG) is subject to regulatory review and other customary closing conditions. Terms of the transaction were not disclosed.

15:24 EDT Takung Art reports agreement to invest in Cultural Objects - In a regulatory filing, Takung Art Co. disclosed that on May 28 the company and Cultural Objects Provenance Holdings Limited, a company with a subsidiary engaged in the operation of an NFT platform related to collectibles, entered into a securities purchase agreement pursuant to which the company shall invest in Cultural Objects through paying a purchase price that consists of $500,000 in cash and the issuance by the company to Cultural Objects of 282,000 restricted shares of the common stock of the company in exchange for 54,100 common shares of Cultural Objects, and, subject to the satisfaction of the conditions listed in the agreement, including, without limitation, the completion by Cultural Objects, to the satisfaction of the company, of an NFT platform for primary market sales and the launch of a physical exhibition / show with sales of collectibles utilizing Cultural Objects' authentication technology to the satisfaction of the company, 290,000 unvested restricted shares of common stock in exchange for 32,460 unvested common shares of Cultural Objects. The closing of the agreement is subject to satisfaction of customary closing conditions, the filing noted.

15:00 EDT Takung Art trading halted, news pending

14:57 EDT AYRO tweets link to report on rising demand for EV trucks - AYRO Inc tweeted: "Very interesting read on how the rise in #ecommerce is increasing demand for #electric #delivery vehicles. AYRO is building compact, light-duty EVs today that can tackle last-mile delivery challenges, while producing zero planet-warming emissions." The tweet from AYRO, which is being circulated by traders, links to a previously published report and was accompanied by an image of an Amazon Prime delivery vehicle. Reference Link

14:53 EDT Walmart U.S. announces store hours to expand starting Saturday, June 5 - Dacona Smith, Executive Vice President and Chief Operating Officer, Walmart U.S., announced in post to the company's blog: "As customers and associates across the country continue to get vaccinated against COVID-19, there is a growing optimism that, as a country, we may soon be able to turn the page on what has been a very challenging time... As cases spiked, you saw us limit shopping hours, step up our cleaning and sanitization measures, broaden access to convenient, no-touch shopping options like pickup and delivery and restrict our entrances to one main door, where our health ambassadors could help support customers. Many of those same policies and processes are in place today, but as the curve flattened over the last year, we felt comfortable making some careful adjustments. Some of our decisions have been to turn something on or off, while others have been more of an evolution... When the pandemic started to hit hard early last year, we restricted our shopping hours. We said then that we would continue to stay very close to the best science and guidance around the virus and make business choices aimed at protecting the health and safety of our customers and associates. As COVID-19 cases leveled out, we expanded our closing time late last year and now, with the number of fully vaccinated Americans growing higher every day, we believe we can adjust hours once again. Starting Saturday, June 5, store hours will expand to 6 a.m.-11 p.m. unless otherwise mandated by state or local government. Also, beginning July 3, we'll be resuming pre-COVID hours for most of our pharmacies and vision centers." Reference Link

14:33 EDT InterPrivate IV InfraTech Partners reports NYSE notice on delayed form 10-Q - InterPrivate IV InfraTech Partners announced that it received a notice from the New York Stock Exchange indicating that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the SEC. The notice has no immediate effect on the listing of the company's stock on the NYSE, the company said. The NYSE informed the company that, under the NYSE's rules, the company can regain compliance with the NYSE's continued listing requirements by filing the Q1 2021 Form 10-Q with the SEC at any time prior to November 24, 2021. As the company reported in its Form 12b-25 filed with the SEC on May 18, 2021, the company is currently determining the extent to which the April 12, 2021 statement released by the Staff of the SEC relating to the accounting and reporting considerations for warrants issued by special purpose acquisition companies, or "SPACs," will impact its financial statements as of and for the fiscal quarter ended March 31, 2021, which will be included in the Q1 2021 Form 10-Q.

14:17 EDT InterPrivate III Financial Partners reports NYSE notice on delayed form 10-Q - InterPrivate III Financial Partners announced that it received a notice from the New York Stock Exchange indicating that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the SEC. The notice has no immediate effect on the listing of the company's stock on the NYSE, the company said. The NYSE informed the company that, under the NYSE's rules, the company can regain compliance with the NYSE's continued listing requirements by filing the Q1 2021 Form 10-Q with the SEC at any time prior to November 24, 2021. As the company reported in its Form 12b-25 filed with the SEC on May 18, 2021, the company is currently determining the extent to which the April 12, 2021 statement released by the Staff of the SEC relating to the accounting and reporting considerations for warrants issued by special purpose acquisition companies, or "SPACs," will impact its financial statements as of and for the fiscal quarter ended March 31, 2021, which will be included in the Q1 2021 Form 10-Q.

14:07 EDT InterPrivate II Acquisition reports NYSE notice on delayed form 10-Q filing - InterPrivate II Acquisition Corp. announced that it received a notice from the New York Stock Exchange indicating that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the SEC. The notice has no immediate effect on the listing of the company's stock on the NYSE, the company said. The NYSE informed the company that, under the NYSE's rules, the company can regain compliance with the NYSE's continued listing requirements by filing the Q1 2021 Form 10-Q with the SEC at any time prior to November 24, 2021. As the company reported in its Form 12b-25 filed with the SEC on May 18, 2021, the company is currently determining the extent to which the April 12, 2021 statement released by the Staff of the SEC relating to the accounting and reporting considerations for warrants issued by special purpose acquisition companies, or "SPACs," will impact its financial statements as of and for the fiscal quarter ended March 31, 2021, which will be included in the Q1 2021 Form 10-Q.

13:49 EDT Retractable Technologies jumps 29% after DHS contract extension notice - Shares of Retractable Technologies are up $2.67, or 29%, to $11.76 in afternoon trading.

13:37 EDT Retractable Technologies receives notice of intent to extend government contract - Retractable Technologies announced that it received a preliminary notice from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response expressing its intent to exercise all seven one-month option periods under 75A50121P00021 contract between HHS/ASPR and Retractable. Such option exercises would extend the contract expiration date to February 14, 2022. As previously disclosed, the option periods increase the value of the contract by $92,772,680, including the price of the products and freight reimbursement.

13:25 EDT Discovery says "Warner Bros. Discovery" to be name for proposed new company - Discovery, Inc. (DISCA, DISCB, DISCK) announced the new name of the proposed standalone entertainment company that will emerge from the combination of AT&T's (T) WarnerMedia and Discovery assets: "Warner Bros. Discovery." Discovery said: "The Warner Bros. Discovery name will honor, celebrate and elevate the world's most-storied creative studio in the world with the high quality, global nonfiction storytelling heritage of Discovery. " David Zaslav, President and CEO of Discovery and the future CEO of the proposed Warner Bros. Discovery, added: "Warner Bros. Discovery will aspire to be the most innovative, exciting and fun place to tell stories in the world - that is what the company will be about. We love the new company's name because it represents the combination of Warner Bros.' fabled hundred year legacy of creative, authentic storytelling and taking bold risks to bring the most amazing stories to life, with Discovery's global brand that has always stood brightly for integrity, innovation and inspiration."

13:01 EDT Walmart's Sam's Club announces return of sampling and demo program - Sam's Club, a division of Walmart, announced the return of its sampling and demo program, Taste & Tips. "Officially re-launching this week, Taste & Tips allows members to sample food and review products when they visit the club. Initially, Taste & Tips will take place on the weekends and in limited quantities, using new safety measures, such as sealed samples. Sam's Club's sampling program has been an attraction in clubs for more than 35 years, but it was paused last March out of concern for the health and safety of members and associates during COVID-19," the company stated.

12:45 EDT BASF reports Heinz takes over as Chairman and CEO of North American affiliate - Effective today, Michael Heinz takes over as Chairman and Chief Executive Officer of BASF Corporation, the North American affiliate of BASF SE, the company announced. Heinz succeeds Wayne Smith, who led BASF Corporation for six years. Heinz has been a member of BASF SE's Board of Executive Directors since 2011 and will continue serving in this role in addition to leading the company's North American activities. As part of his Board duties, Heinz is also responsible for BASF's global Chemicals and Materials business segments as well as the South America region, the company stated.

12:00 EDT LoanDepot falls -8.1% - LoanDepot is down -8.1%, or -$1.38 to $15.57.

12:00 EDT Renren falls -14.2% - Renren is down -14.2%, or -$1.76 to $10.60.

12:00 EDT Cloudera rises 23.9% - Cloudera is up 23.9%, or $3.08 to $15.94.

11:55 EDT Telos director Maluda sells 40,000 common shares - In a regulatory filing, Telos director John Maluda disclosed the sale of 40,000 common shares of the company on May 27 at a price of $33.16 per share.

11:43 EDT Tarsadia urges Extended Stay shareholders to vote against proposed sale - Tarsadia Capital, together with its affiliates, associates and funds it manages, commented on the updated offer from Blackstone Real Estate Partners (BX) and Starwood Capital Group to acquire Extended Stay America (STAY). Tarsadia continues to urge shareholders to Vote Against the proposed sale on the GOLD card at the Special Meeting scheduled for June 8, 2021. Tarsadia issued the following statement: "A $1 bump in price is a small Band-Aid that cannot cure a fatally flawed process. The updated offer announced today, representing just a 5% increase over the previous price, is nothing more than an attempt to jam through a transaction that still significantly undervalues the Company and was the result of a process that was not designed to elicit the highest bid for STAY or create competition for Blackstone and Starwood. Notably, both leading independent proxy advisory firms, Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC, in their reports recommending shareholders vote against the Sale, concluded there were serious flaws in the sale process, valuation and timing of the transaction. We continue to urge shareholders to vote Against the Sale."

11:30 EDT EMA recommends added manufacturing capacity for BioNTech/Pfizer vaccine - The EMA announced that it has recommended the approval of additional manufacturing and filling lines at Pfizer's (PFE) vaccine manufacturing site in Puurs, Belgium. "The recommendation by the Agency's Committee for Human Medicines is expected to have a significant and immediate impact on the supply of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer, in the European Union," the EMA stated. Reference Link

11:02 EDT Clearwater Paper announces closure of Neenah, Wisconsin facility - Clearwater Paper announced the indefinite closure of its Neenah, Wisconsin facility, which includes three tissue machines and ten converting lines, removing a total paper production capacity of approximately 54,000 tons. Clearwater Paper intends to indefinitely close Neenah and exit the away from home business by the end of July 2021. Clearwater Paper acquired the Neenah mill in 2010 and produced private brand tissue products for commercial and retail customers at the mill. The facility's approximately 290 employees will be impacted by the closure. "Despite the best efforts of our dedicated employees, our Neenah location and assets cannot cost effectively compete in the markets that we serve. This was a difficult decision, because it affects our people, their families and the Neenah community. We are committed to supporting our people through this challenging time," said CEO Arsen Kitch. The company and the union will be meeting this week to discuss the impact on employees, Clearwater stated.

10:46 EDT Shattuck Labs appoints Abhinav Shukla as CTO - Shattuck Labs announced the appointment of Abhinav Shukla, Ph.D., as chief technical officer. Shukla joins Shattuck from Redpin Therapeutics, where he was the Chief Technical Operations Officer and was responsible for all aspects of process, analytical and formulation development, and cGMP manufacturing.

10:36 EDT Sinovac Covid vaccine validated for emergency use by World Health Organization

10:25 EDT Candy Digital announces long-term NFT agreement with MLB - Candy Digital announced earlier this morning that it is entering the NFT, or "non-fungible token," space with "three of the world's most innovative companies across sports, e-commerce, technology, collectibles and cryptocurrency" along with an exclusive long-term agreement with its first content partner Major League Baseball. "Candy Digital is being launched by three titans of their respective industries who bring unique expertise and skill sets for scaling businesses within the digitally native world: Michael Rubin, Executive Chairman, Fanatics; Mike Novogratz, founder and CEO, Galaxy Digital; and Gary Vaynerchuk, Serial Entrepreneur and Investor. Leveraging deep experience in sports, e-commerce, fintech, blockchain, pop culture and digital media, the founders and their respective companies have positioned Candy to enter the digital asset marketplace with significant resources, skills, and capabilities," the company stated. "Candy is building Major League Baseball's official NFT ecosystem where fans and collectors will be able to purchase, trade and share officially licensed NFTs to deepen their love of the sport. Candy's team of world class digital artists, designers and technologists are developing a broad range of digital collectibles, beginning with sports content and expanding into art, entertainment, music and more. Candy's NFTs will be available on its online platform where fans will be able to purchase, collect, view, and trade via a branded storefront and secondary marketplace... Candy and Major League Baseball's first release will be a 1-of-1 NFT of Lou Gehrig's famous "Luckiest Man" speech that he delivered on July 4, 1939, after being diagnosed with ALS," the company added. The Topps Company, which offers a series of trading-card-style NFTs from MLB, previously announced a definitive agreement for a business combination with Mudrick Capital Acquisition Corporation II. Upon closing of the transaction, which is expected in late second or early third quarter, the combined company will be named Topps and remain listed on NASDAQ under the new ticker symbol "TOPP." In morning trading, Mudrick Capital Acquisition Corporation II shares are down 80c, or 6%, to $12.85.

10:05 EDT Pegasystems, The Ryder Cup enter multi-year agreement - The Ryder Cup and Pegasystems announced a multiyear agreement establishing Pega as a worldwide supplier of the 43rd and 44th Ryder Cup. Pega's sponsorship will contribute toward the distinguished experience both teams and spectators have come to expect from this event. Pega will also work with Ryder Cup broadcast partners to create online content on the value of partnerships.

10:03 EDT BeiGene says data from Phase 3 ALPINE trial to be presented at EHA - BeiGene announced that results from the interim analysis of the Phase 3 ALPINE trial comparing BRUKINSA to ibrutinib in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma will be reported in an oral presentation as part of the Presidential Symposium at the 26th European Hematology Association 2021, or EHA2021, Virtual Congress. Results from the interim analysis were based on 415 enrolled patients in the trial, including 207 on BRUKINSA treatment and 208 on ibrutinib treatment. As previously announced, the ALPINE trial met its primary endpoint, with BRUKINSA demonstrating non-inferiority in objective response rate, or ORR, per investigator assessment and independent review committee, and superiority in ORR per investigator assessment. The trial also met a pre-specified secondary endpoint related to safety, with BRUKINSA demonstrating a statistically significant lower risk of atrial fibrillation or flutter, compared to ibrutinib. More details on the ALPINE trial results will be provided by Peter Hillmen, MBChB, Ph.D., Professor of Experimental Haematology at University of Leeds and trial investigator, in an oral presentation at EHA2021 on Friday, June 11. "The positive topline results from the Phase 3 ALPINE trial interim analysis suggest that BRUKINSA could improve clinical benefit for patients with CLL, compared to the first-generation BTK inhibitor. BRUKINSA was designed to optimize selectivity and deliver sustained BTK inhibition, and we hope our bold approach in its clinical development, including two head-to-head trials, can provide additional evidence to support its potential as a best-in-class BTK inhibitor. We look forward to the first presentation of these data in the Presidential Symposium at EHA," said Jane Huang, M.D., Chief Medical Officer, Hematology at BeiGene.

10:02 EDT Inter Pipeline tells holders to reject 'hostile' Brookfield Infrastructure bid - Inter Pipeline (IPPLF) reiterated its recommendation that shareholders "reject a hostile takeover bid" at a value of $16.50 per share from an affiliate of Brookfield Infrastructure Partners (BIP). Inter Pipeline's board has "unanimously determined that the Hostile Bid is not in the best interests of the Company or its shareholders." As disclosed separately today, the board is recommending that shareholders support a strategic combination with Pembina Pipeline (PBA). Inter Pipeline shareholders will receive 0.5 of a share of Pembina for each share of Inter Pipeline that they own. The consideration is valued at $19.45 per share of Inter Pipeline based on the closing price of Pembina common shares on May 31.

10:01 EDT Capri Holdings promotes Hendricks to Senior Vice President, Chief People Officer - Capri Holdings announced that Jenna Hendricks will be promoted to Senior Vice President, Chief People Officer effective June 1, 2021. In this role, Hendricks will be responsible for leading the global human resources organization for Capri Holdings across all three luxury houses to further drive innovative solutions that promote a talent-centric culture. Hendricks will continue to report to John Idol, Chairman and CEO.

10:00 EDT GigCapital2 falls -6.6% - GigCapital2 is down -6.6%, or -67c to $9.41.

10:00 EDT AMC Entertainment rises 16.0% - AMC Entertainment is up 16.0%, or $4.19 to $30.31.

10:00 EDT Washington Prime rises 48.6% - Washington Prime is up 48.6%, or $1.08 to $3.30.

09:51 EDT Disney's ABC stations support adoption of impressions-based currency - Debra OConnell, President, Networks - Disney Media & Entertainment Distribution, released the a statement regarding the adoption of impressions-based selling and buying for local broadcast television: "Today, the ABC Owned Television Stations provide best in class content that serves our communities on a variety of video platforms, including linear, digital and OTT. Marketers with local strategies want to build multiplatform campaigns and need a common currency to do so effectively. Using an impressions-based currency to evaluate, sell and buy local broadcast video enables us to offer our advertisers full visibility into local audiences and extends the overall reach of their messaging across platforms. The ABC Owned Television Stations fully support the adoption of impressions as the currency for local broadcast TV."

09:47 EDT Virgin Galactic falls -6.4% - Virgin Galactic is down -6.4%, or -$2.00 to $29.23.

09:47 EDT Peabody Energy rises 10.1% - Peabody Energy is up 10.1%, or 67c to $7.30.

09:47 EDT Cloudera rises 23.8% - Cloudera is up 23.8%, or $3.06 to $15.93.

09:39 EDT MassRoots issues update on expected acquisition of Empire Services - MassRoots released the following update on its expected acquisition of Empire Services and plans to meet the listing requirements and apply to list its shares of common stock on a national exchange. MassRoots recently entered into a Letter of Intent to acquire Empire, which is expected to result in MassRoots generating significant revenues and positive cashflows from operations. Upon closing of the Empire acquisition, the company intends to apply to uplist to the Nasdaq Capital Market or the NYSE American Market, which MassRoots believes would result in a significant increase in visibility, liquidity, and institutional interest for its stock. Upon closing of the merger, Meeks will join MassRoots' Board of Directors as its Executive Chairman.

09:34 EDT Silversea Cruises announces summer voyages in Alaska, Iceland - Silversea Cruises has announced new summer voyages in Alaska and Iceland, starting in July 2021. With the passage of the U.S. Alaska Tourism Restoration Act, which enables cruises to Alaska without required stops in Canada, Silver Muse will resume round-trip sailings from Seattle starting July 29, making Silversea the first ultra-luxury cruise line to operate in Alaska this summer. Silver Shadow will circumnavigate Iceland with the launch of new all-Icelandic itineraries, returning to Northern Europe with three 10-day voyages from Reykjavik, beginning July 30.

09:31 EDT SpartanNash appoints Douglas Hacker as chairman of the board - SpartanNash Company announced the appointment of Douglas Hacker as Chairman on its Board of Directors. The announcement follows SpartanNash's appointments of three new executive officers, six vice presidents and 11 directors in 2021, as well as the addition of Tony Sarsam as President and CEO in September 2020. Hacker was officially voted in as Chairman after the Company's 2021 annual shareholder meeting on May 26. He previously served as a Director of Nash Finch since 2005, prior to its merger with SpartanNash in 2013. He has acted as SpartanNash's Lead Independent Director since May 2018, and his appointment as Chairman follows former Chairman Dennis Eidson's retirement.

09:27 EDT CytoDyn, Philippine Airlines collaborate for transportation of leronlimab - CytoDyn announced a joint collaborative effort with Philippine Airlines as the preferred partner in transporting leronlimab to the Philippines for treatment of critically ill COVID-19 patients. CytoDyn recently provided the Philippines with enough leronlimab to treat 100 patients free of charge, distributed locally by Chiral Pharma Corporation for patients under Compassionate Special Permit. Philippine Airlines has stepped up to help with one of the main challenges, the long delivery time from the USA to the Philippines. The flag carrier will help transport vials from Los Angeles to Manila on PAL's nonstop flights, enabling the delivery of leronlimab to critical patients as quickly as possible.

09:24 EDT W.R. Grace completes acquisition of Fine Chemistry business - W. R. Grace & Co. (GRA) announced the completion of its acquisition of the Fine Chemistry Services business of Albemarle Corporation (ALB) for approximately $570 million, including $300 million paid in cash and $270 million funded through the issuance to Albemarle of non-participating preferred equity of a newly created Grace subsidiary.

09:21 EDT Genius Brands names Never Wrong Toys as global master toy partner - Genius Brands International and Never Wrong Toys announce the appointment of Never Wrong Toys as global master toy partner for the animated series, Rainbow Rangers, available for streaming now on Kartoon Channel!, and from July on Netflix in the U.S., Canada, U.K., Australia, New Zealand, and the Middle East., Amazon Prime Direct in U.S. and U.K., and HBO Max Lat Am, joining Nick Lat Am, as well as key broadcasters around the world. Genius Brands and Never Wrong Toys will collaborate to develop a broad range of preschool products in the toy category, including dolls/figures, playsets, plush, vehicles, technology and interactive toys, musical toys, role play and much more. The toy line is anticipated to hit the retail market in Q1 2022 to coincide with the premiere of season three of Rainbow Rangers, exclusively on Kartoon Channel!

09:19 EDT CytoDyn recieves purchase order from Chiral Pharma for leronlimab use - CytoDyn announced that Chiral Pharma Corporation in the Philippines placed its first purchase order for leronlimab under a Compassionate Special Permit to treat critically ill COVID-19 patients in the Philippines. The Company expects to recognize revenues related to this purchase order upon fulfillment of the purchase order and the terms of the agreement.

09:17 EDT Salesforce and Combs Enterprises partner to create Shop Circulate marketplace - Combs Enterprises and Salesforce have teamed up to create SHOP CIRCULATE, a curated digital marketplace that allows consumers to discover and buy products exclusively created and sold by Black entrepreneurs. This new platform will be designed and built by Deloitte Digital, a leading Experience Consultancy and global strategic partner for Salesforce, and powered by Marketplacer's best-in-class online marketplace technology.

09:13 EDT CarLotz to open hub in Denver, Colorado - CarLotz announced it will open a hub in Denver, Colorado. Located at 8120 West Tufts Avenue in Denver, the hub is the first for CarLotz in Colorado and in the Rockies. It is expected to open later this year.

09:11 EDT CarLotz to open hub for St. Louis metro area - CarLotz announced it will open a hub to serve the St. Louis metro area. Located just outside of St. Louis at 1807 W Highway 50 in Fairview Heights, Illinois, the hub will provide CarLotz's guests in the greater St. Louis market with easy access to its service, value and inventory. The hub is expected to open later this year.

09:09 EDT Progress Software announces release of Progress DataDirect connectors - Progress announced the release of new Progress DataDirect connectors that seamlessly integrate with AWS Glue and dramatically simplify real-time data movement between a variety of data sources. The connectors are currently available in the AWS Marketplace. A serverless data integration service, AWS Glue makes it easy for anyone to discover, prepare and combine data for analytics, machine learning and custom application development on Amazon Web Services. While AWS Glue natively supports connectivity to AWS services, there is an ever-growing market of applications and databases that need to be accessed but are not directly accessible to AWS Glue processes. With DataDirect connectors for AWS Glue, users can easily access real-time data directly from AWS Glue, breaking down data silos to gain actionable insights.

09:07 EDT Crestwood Equity, Consolidated Edison announce divestiture of Stagecoach Gas - Crestwood Equity Partners (CEQP) and Consolidated Edison (ED) announced that their subsidiaries entered into a purchase and sale agreement to divest Stagecoach Gas Services to a subsidiary of Kinder Morgan (KMI) for $1.225B. The cash proceeds from the divestiture will be split pro rata between Crestwood and Con Edison in line with each member's 50% ownership interest in the joint venture. The agreement was signed on May 31 and is subject to two closing periods. The first closing consists of the transfer of the Stagecoach subsidiaries (with the exception of Twin Tier Pipeline LLC) valued at $1.195B, and is expected to occur following approval under Hart-Scott-Rodino, during the third quarter.

09:06 EDT AB InBev achieves 2025 renewable electricity sustainability goal - Anheuser-Busch announced today that its entire portfolio of domestic beer and seltzer brands - including Bud Light, Michelob ULTRA, Busch and its Brewers Collective family of craft partners - is now brewed with 100% renewable electricity from solar and wind power. The Anheuser-Busch Solar Farm, the brewer's 222MWac solar project in Texas, officially comes online this month, marking the early achievement of Anheuser-Busch's Sustainability Goal to source 100% of its purchased electricity from renewables by 2025.

09:04 EDT Shift executives announce purchase of shares - Shift announced completed purchases of SFT Class A common stock on the open market by certain Section 16 and other executives: Co-Founder and Co-CEO Toby Russell; Co-Founder and Co-CEO George Arison; CFO Oded Shein; and CRO Mark McCollum.

09:04 EDT Harrow Health launches new corporate, investor website - Harrow Health announced the launch of its newly redesigned corporate and investor website, harrowinc.com. The new website, which is mobile-friendly, improves functionality and provides easy access to both historical and current information on the Company, including Letters to Stockholders and its Corporate Presentation. The website also provides detailed information about Harrow Health's journey to becoming one of the leading eye health companies in the United States, along with the Company's mission, vision and values, its product pipeline, and its quest to be a part of providing the gift of eyesight to Americans and people in areas around the world where eyecare isn't as readily available or affordable.

09:03 EDT Valaris awarded well contract with Total E&P Cote d'Ivoire - Valaris announced that it has been awarded a one-well contract with Total E&P Cote d'Ivoire B.V. offshore Ivory Coast for drillship, VALARIS DS-12. The contract is expected to commence in the Q3.

09:03 EDT Workday announces continued momentum with healthcare solution - Workday announced continued momentum, with its healthcare solution, including supply chain management. New customers including the Medical University of South Carolina, Northeast Georgia Health System, Sentara Healthcare, and Sharp HealthCare have selected Workday to help transform operations to support new business models and improve care delivery. In addition, organizations such as Allina Health, Bon Secours Mercy Health, South Shore Health, and Spectrum Health were able to shift to virtual deployments amid the COVID-19 pandemic, going-live on schedule, helping maintain business continuity and improving medical supply management to support patient care.

09:02 EDT Encore Capital completes offering of senior secured notes - Encore Capital Group announced that it has completed its offering of GBP250 million aggregate principal amount of 4.25% senior secured notes due 2028. Encore used the proceeds from the offering to redeem in full the outstanding GBP226.2 million 7.50% senior secured notes due 2023 and to pay certain transaction fees and expenses incurred in connection with the offering of the Notes. In the second quarter of 2021, the Company expects to record charges related to the offering totaling approximately $8 million after tax.

09:00 EDT Old National Bancorp trading resumes

08:59 EDT Brooge Energy clients renew 233,072 cbm of storage capacity - Brooge Energy announced its customers have successfully renewed their fixed lease contracts for 233,072 cbm of Brooge Energy's Phase I storage capacity, at a premium that is 70% higher than the starting fixed lease storage price of the earlier contracts. The contract renewals consist of a total of 190,072 cbm signed with two clients on three-year terms each consisting of one year plus a two-year mutual renewal clause. The remaining 43,000 cbm was renewed by a client for a three-year term consisting of six months plus six months, subject to mutual renewal for an additional two years.

08:52 EDT DTE Energy and AHF announce museum's enrollment in DTE's MIGreenPower program - DTE Energy and the Automotive Hall of Fame, AHF announced the museum's enrollment in DTE Energy's MIGreenPower program. The first museum to enroll in DTE's MIGreenPower program, the AHF will attribute 100% of its energy use to Michigan wind and solar projects. Additionally, the museum has enrolled in Charging Forward, DTE's electric vehicle charging incentive program and now has two charging stations in the parking lot available for visitors with EVs. DTE also performed an energy audit at the museum, a complimentary service the company offers to qualified customers. As a result of the audit, DTE is working with the museum to achieve cost savings by installing energy efficient lighting and implementing other measures to reduce energy usage. "While the Automotive Hall of Fame celebrates our industry's past, we also showcase its future," said Ramzi Hermiz, chairman of the Automotive Hall of Fame Board of Directors. "Embracing clean energy and doing our part to reduce emissions goes hand in hand with the evolution we are seeing in the automotive and mobility markets. We appreciate the support and guidance we've received from DTE Energy toward becoming a carbon-neutral institution."

08:51 EDT Assure Holdings enters in-network agreement with Louisiana health insurer - Assure Holdings announced that it has signed an agreement with a commercial health insurer in the state of Louisiana with whom it has had a protracted dispute. The Agreement is effective retroactively as of May 1, 2021, and allows the Company to provide its professional telehealth neurology services for IONM as an in-network healthcare provider of the Insurer in Louisiana. The Agreement will help streamline the Company's billing and collections process in Louisiana by including contracted rates, payment of claims within 45 days, medical necessity conditions and dispute resolution steps. The Agreement includes a right for both parties to terminate the Agreement with 90 days' written notice. In addition, the Insurer has committed to expedite all open claims since January 1, 2020, at the contracted rates. The Agreement concludes a protracted negotiation with the Insurer over a dispute in which cases were performed, services were rendered by Assure and associated claims were submitted, but reimbursement associated with the services performed by Assure were not subsequently made by the payor.

08:50 EDT Hollister announces collection co-created by GLSEN student activists - Hollister is celebrating PRIDE Month and the fifth year of its partnership with GLSEN by launching a limited-edition product collection co-created with GLSEN's National Student Council Members. This gender-neutral collection is designed to highlight the beautiful ways to celebrate PRIDE and is made to help customers be their most proud, powerful selves. The collection, which can be shopped online and in stores, features more than 40 PRIDE-themed styles to wear no matter how you choose to celebrate. The product, ranging from tees and shorts, to lounge, swimwear, dresses, fragrance and underwear, is gender-neutral and showcases PRIDE representation across the LGBTQIA+ spectrum. Styles in the PRIDE collection range in price from $9.95 to $49.95.

08:49 EDT WisdomTree lists bitcoin, ether ETPs on Euronext - WisdomTree has announced its physically-backed bitcoin and ether ETPs have listed on Euronext exchanges in Paris and Amsterdam. WisdomTree Bitcoin and WisdomTree Ethereum each have a total expense ratio of 0.95% and are already listed on Germany's Borse Xetra and SIX, the Swiss Stock Exchange. The listings of BTCW and ETHW on the Euronext exchanges follow a series of new developments across WisdomTree's digital assets platform. In April, ETHW launched on Borse Xetra and SIX. Also in April, BTCW listed on Borse Xetra. WisdomTree offers Europe's lowest priced physically-backed bitcoin and ether ETPs.

08:47 EDT MusclePharm closes four more distributors for MP Performance Energy line - MusclePharm Corporation reported that they secured distribution with four additional distributors: Nutrition Systems, a distributor of sports nutrition in Australia and New Zealand, Muscle & Strength, a distributor in the online sports nutrition space, Muscle Foods USA, a domestic nationwide and military sports nutrition supplier, and DNA Sports Nutrition, a distributor of drinks, bars, and nutritional supplements in the United States. MP Energy is slated to begin distribution in summer, 2021.

08:45 EDT TriumphPay closes acquisition of Hubtran - TriumphPay announced that it has closed the previously announced acquisition of HubTran, a cloud-based provider of automation software for the transportation industry's back-office. As a result of this acquisition, HubTran will operate as a service of TriumphPay. TriumphPay and HubTran will continue to operate as independent brands until the full integration of the platform is completed, which is expected to occur in the fourth quarter of 2021. Under the terms of the agreement, TriumphPay acquired HubTran for $97M in cash subject to customary purchase price adjustments.

08:44 EDT XpresSpa announces launch of treatcare.com - XpresSpa Group announced the launch of Treat , a new travel brand that provides access to integrated care services that can seamlessly fit into a health and wellness lifestyle. Empowering travelers to take a health-first approach to the journey ahead, Treat will act as a wellness concierge, providing medical care and wellness services to consumers as they return to travel. "We are elated to announce the launch of Treat, our new lifestyle brand designed to accompany travelers wherever in the world they may go. With a focus on life-long wellness, we look forward to providing our members with an unencumbered confidence to travel, thanks to the knowledge that they have constant medical and wellness support at their fingertips," said Doug Satzman, XpresSpa CEO. "Treat is positioned for a post-pandemic world and designed to deliver on-demand access to integrated healthcare through technology and personalized services. Travelers will be able to access health care, records and real-time information all in one place, as we will feature original content, access to resources about global COVID-19 requirements, and curated e-commerce. Memberships, available later this summer, will provide a mobile app subscription with access to integrated medical and wellness care, virtually and physically in select airports. Treat's mobile app, launching later this summer, will provide access to on-demand virtual care, including chat care, video care and a "travel wallet" with access to a person's medical records and test results.

08:41 EDT Aterian announces certain stockholders agree to lock-up pacts - Aterian announced that certain stockholders have voluntarily entered into lock-up agreements with the Company with respect to an aggregate of 4,058,116 shares of common stock or 13.3% of the total issued and outstanding shares of common stock of the Company as of March 31. Aterian's Co-Founder and CEO, Yaniv Sarig, agreed to lock up all of the shares that he controls through January 1, 2022. Also included among the Stockholders are the Company's co-founders, Asher Delug and Maximus Yaney as well as certain sellers in Aterian's recent asset acquisitions, 9830 Macarthur and Healing Solutions. Asher Delug and Maximus Yaney agreed to lock up a portion of the shares that they control through December 1, 2021, and 9830 Macarthur LLC and Healing Solutions LLC have each agreed to extend, with respect to a portion of their shares, the lock-up agreements entered into in connection with Aterian's asset acquisitions to December . The lock-up agreements stipulate that these stockholders will not sell, pledge, assign, transfer, hypothecate or otherwise dispose of any of the Lock-up Shares, or enter into any swap, hedge or engage in any short-selling of the Lock-up Shares, in addition to other restrictions. Yaniv Sarig, Co-Founder and CEO of Aterian, commented, "The lock-up agreements announced today reflect the continued confidence that I and other large Aterian stockholders have in the long term prospects of the Company."

08:39 EDT Lumine Group completes acquisition of Neural Technologies - Lumine Group announced that it has completed the acquisition of Neural Technologies, a provider of modular revenue protection, signalling, machine learning and artificial intelligence software for telecom operators. Its revenue assurance suite includes capabilities for fraud management, revenue assurance, credit-risk management, business assurance, and anti-money laundering. Its ML and AI capabilities assist telecom operators with data integration and customer engagement. Neural is Lumine's 19th acquisition, further establishing Lumine's position as a leading global acquirer of communications and media software businesses.

08:38 EDT Tracon Pharmaceuticals says IDMC recommends continuation of ENVASARC trial - TRACON Pharmaceuticals announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial will proceed as planned following the review of safety data from more than 20 patients enrolled into the trial to date. The safety data reviewed included data from more than 10 patients enrolled into cohort A of treatment with single agent envafolimab and more than 10 patients enrolled into cohort B of treatment with envafolimab and Yervoy.

08:37 EDT Bioceres receives approval of HB4 drought soybean in Canada - Bioceres Crop Solutions announced it has successfully completed the regulatory review process and received approval for its HB4 drought and herbicide tolerant soybeans from the Canadian Health Agency and the Canadian Food Inspection Agency. Currently, HB4 soybean is approved for production in the United States, Brazil, Argentina and Paraguay, collectively representing, together with Canada, 85% of the world's hectarage dedicated to the crop.

08:37 EDT PlantX To launch on Walmart Canada marketplace - PlantX Life is pleased to announce that it has entered into an agreement to launch as a seller on Walmart Canada Marketplace. Walmart Canada Marketplace was launched in 2009 and integrates a curated community of respected and well-known retailers that aim to offer consumers high-quality and reputable products. The new collaboration will enable PlantX to take advantage of the extensive Walmart Canada Marketplace digital marketing services and customer base. PlantX on Walmart Canada Marketplace will initially sell grocery and pantry items from various brands such as Simply Organic, Made in Nature, Cadia and Nutiva, with potential opportunities to diversify its offerings on this platform in the future.

08:36 EDT Firm Capital Mortgage CFO Boris Baril resigns - Firm Capital Mortgage Investment Corporation hereby announces that Boris Baril has resigned as CFO of the Corporation effective immediately. In the interim, Sandy Poklar has been appointed CFO until such time as the Corporation finds a permanent replacement, subject to TSX and regulatory approval.

08:35 EDT Ametek appoints Stewart Douglas as CIO - AMETEK announced that its Board of Directors has elected Stewart Douglas as Vice President and CIO, following the retirement of Ken Weirman who held the same position since joining AMETEK in 2010. Douglas joined AMETEK in 2007, serving as Division Vice President of Businesses Systems for the Aerospace & Defense and Power divisions. Prior to joining AMETEK, Mr. Douglas served as IT Director at Rohm and Haas, European IT Manager at Shipley Europe, and European IT Manager at ITT Cannon.

08:33 EDT TripAdvisor and Trip.com Group expand strategic partnership - Trip.com Group (TCOM) and Tripadvisor (TRIP) announced an expansion of the strategic partnership first announced in November 2019, including a new commercial arrangement and waiver under the Governance Agreement. Trip.com and Tripadvisor have agreed to expand their strategic partnership to include Tripadvisor Plus. Initially, Trip.com will provide access to preferential pricing on at least 10,000 properties to benefit the Tripadvisor Plus offering, Tripadvisor's new, direct-to-consumer subscription service. This collaboration, to be launched later this year, is expected to be expanded over time. Concurrently, Trip.com has been granted approval under the Governance Agreement to sell a portion of its holdings in Tripadvisor, which at April 16 consisted of approximately 6.95M shares, to meet its corporate needs. Sales by Trip.com are expected to occur in multiple tranches throughout 2021. Trip.com has relinquished its contractual right under the Governance Agreement to nominate a director to the Tripadvisor board of directors, which position has been held by Trip.com Group CEO, Jane Sun. As an indication of the commitment to the ongoing relationship between the companies, Sun will continue to serve on the Tripadvisor board, subject to the typical shareholder voting process.

08:32 EDT Standard Motor acquires capital stock of Trumpet Holdings for $108M - Standard Motor Products announced that it has acquired 100% of the capital stock of Trumpet Holdings a Delaware corporation for $108M subject to certain post-closing adjustments. Trombetta is a worldwide leader in providing power switching and power management products to OE customers in various markets. Trombetta generates approximately $60M in annual revenue, and has manufacturing facilities in Milwaukee, Wisconsin, Sheboygan Falls, Wisconsin, and Tijuana, Mexico, as well as a majority ownership in a joint venture in Wuxi, China. SMP will fund the acquisition in cash through borrowings under its revolving credit facility. We anticipate the acquisition will be accretive to earnings in 2021.

08:31 EDT Enlivex Therapeutics announces Canadian issuance of pharma composition patent - Enlivex Therapeutics announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 2,893,962 covering Allocetra, the Company's immunotherapy product candidate. The new patent is expected to provide added intellectual property protection for pharmaceutical compositions, manufacturing methods and uses of Allocetra. Oren Hershkovitz, PhD, CEO of Enlivex, stated, "We are pleased to have this patent granted in Canada, which adds to existing Allocetra patents in various countries around the world. We currently continue to focus our clinical development efforts on life-threatening diseases with high mortality rates and no effective treatments such as sepsis, COVID-19, and solid tumors." Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism

08:30 EDT Adverum Biotechnologies appoints Julie Clark as CMO, Brigit Riley as CSO - Adverum Biotechnologies announced the appointment ofJulie Clark, M.D., as chief medical officer, and Brigit Riley, Ph.D., as chief scientific officer effective immediately, both reporting directly to Laurent Fischer, M.D., Adverum's CEO. As chief medical officer, Dr. Clark will be responsible for clinical strategy and implementation of clinical trials across all phases of development. As lead medical director - retina, she was responsible for the Phase 3b clinical trial for BEOVU and served as medical lead for cross-functional team initiatives for product launch. In her position as chief scientific officer, Dr. Riley will be responsible for leading Adverum's portfolio of drug discovery and development programs. Most recently Dr. Riley has been an advisor to several gene therapy companies. On June 1, 2021, Adverum granted Dr. Riley a stock option to purchase 450,000 shares of Adverum's common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to her entering into employment with Adverum. The option has a per share exercise price equal to the closing sales price of Adverum's common stock on the Nasdaq Stock Market on the grant date, and will vest over four years, subject to her continued service with Adverum.

08:27 EDT UFINET selects Infinera's ICE6 800G technology for Colombia network - Infinera announced that UFINET selected Infinera's industry-leading ICE6 800G coherent technology for its new national long-haul network in Colombia. This deployment will double the capacity of UFINET's current network, enabling it to meet the growing bandwidth needs of its customers and provide connectivity in regions currently unconnected. Deploying Infinera's ICE6-powered Compact Modular Platform on UFINET's network will enable the company to cost-effectively and seamlessly increase the number of connectivity services it can provide to its customers.

08:25 EDT Orbital Energy's subsidiary awarded project in Central Mississippi - Orbital Energy Group announced that its recently acquired subsidiary, Gibson Technical Services, or GTS, has been awarded a project for approximately 700-miles of engineering and construction turnkey services across Central Mississippi to be completed over the next four years for TEC of Jackson. GTS began the first engineering phase of the Project in April with construction slated to start in June 2021. The Project is being funded with both private TEC capital and from the Federal Government's Rural Digital Opportunity Fund, or RDOF, for rural fiber buildouts. The RDOF extends the Federal Communication Commission's Connect America Fund and will provide $20.4B in funding over a ten-year period to support broadband networks in rural communities across the country. This partnership between TEC and GTS creates one of the first RDOF rural builds to be started in the U.S.

08:25 EDT Old National Bancorp trading halted, news pending

08:21 EDT Abiomed acquires preCARDIA, a medical device company - Abiomed has acquired preCARDIA, developer of a proprietary catheter and controller. "The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and promoting decongestion to improve overall cardiac and renal function," the company said. preCARDIA completed enrollment of 30 patients in an FDA early feasibility study, which demonstrated acute technical success and significant reduction in cardiac filling pressures and rapid diuresis. Additionally, all patients were free of device- or procedure-related major adverse events through 30 days. "We look forward to advancing preCARDIA's technology through the regulatory process and expanding our relationship with heart failure specialists to help improve outcomes in early stage acute decompensated heart failure patients, a new patient population for Abiomed," said Michael R. Minogue, Abiomed's Chairman, President and CEO. "This acquisition aligns with Abiomed's principles of leading in technology and innovation and putting patients first." The preCARDIA system is available for investigational use only and is not approved for use outside of clinical studies.

08:18 EDT Eucrates Biomedical Acquisition receives not in compliance letter from Nasdaq - Eucrates Biomedical Acquisition announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250 because the Company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31 with the SEC. The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. Under Nasdaq rules, the Company has 60 calendar days from the date of the Notice to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-Q, or until November 22, 2021, to regain compliance.

08:17 EDT Blackstone, Starwood raise offer to acquire Extended Stay to $20.50 per share - Extended Stay America (STAY), Blackstone Real Estate Partners (BK) and Starwood Capital Group announced that they have signed an amendment to their previously announced definitive merger agreement. Under the terms of the merger agreement, as amended, a 50/50 joint venture between funds managed by Blackstone and Starwood Capital will now pay STAY shareholders an additional $1.00 per paired share in cash for a total consideration of $20.50 per paired share in cash. The merger agreement, as amended, has been unanimously approved by the entire boards of directors of both ESA and ESH. The $20.50 per paired share consideration represents the Blackstone/Starwood Capital joint venture's best and final offer and a 21.0% premium over the closing STAY price of $16.94 on March 12, 2021, the last trading day prior to the execution of the merger agreement on March 14, 2021. The Company encourages shareholders to consider the meaningful downside risk recognized by independent third parties in the event a transaction is not approved. The Company notes that the amended transaction represents an implied 30.3% premium, which ranks in the 81st percentile of precedent REIT all-cash transactions since 2013, based on the extrapolated STAY stock price since the March 15th announcement over which time lodging companies have traded down 7.1%.1 In order to ensure STAY shareholders have sufficient time to consider the amended merger agreement, the Special Meetings of the Shareholders of the Company scheduled for June 8, 2021 will be convened and then adjourned. The ESA Special Meeting will be reconvened on June 11, 2021, at 8:30 a.m., Eastern Time, and the ESH Special Meeting will be reconvened on June 11, 2021, at 9:30 a.m., Eastern Time. The reconvened Special Meetings will be held exclusively online via a live audio webcast at www.virtualshareholdermeeting.com/STAY2021SM. The record date for the Special Meetings will remain April 19, 2021. The transaction has received all regulatory approvals and is on track to close on June 16, 2021 pending shareholder approval at the reconvened Special Meetings on June 11, 2021. The Company's boards of directors both unanimously recommend that STAY shareholders vote to approve the transaction at the reconvened Special Meetings of Shareholders.

08:17 EDT Medley Management receives not in compliance letter with NYSE listing rules - Medley announced that it received a notice from the NYSE indicating that Medley is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31 with the SEC. The notice has no immediate effect on the listing of Medley LLC's notes on the NYSE. The NYSE informed Medley that, under the NYSE's rules, Medley can regain compliance with Section 802.01E of the NYSE listing requirements by filing the Form 10-Q with the SEC at any time prior to November 24. If Medley fails to file the Form 10-Q by that date, the NYSE may grant, in its sole discretion, a further extension of up to six additional months for Medley to regain compliance, depending on the specific circumstances. Although Medley plans to file the Form 10-Q as soon as possible after completion and finalization of Form 10-Q financial statements and disclosures and completion of review processes, Medley is unable to predict a specific filing date at this time. The Company continues to work diligently to complete and finalize the 10-Q and intends to file the Form 10-Q as soon as practicable.

08:15 EDT II-VI introduces 100 Gbps indium phosphide DMLs - II-VI Incorporated announced the introduction of 100 Gbps indium phosphide directly modulated lasers for high-speed transceivers deployed in datacenters. The growing demand for 400 and 800 gigabit Ethernet transceivers is driving substantial investments in technology advancements of DMLs due to their lower cost and lower power consumption compared to electro-absorption modulated lasers currently used in these high-speed transceivers. II-VI's 100 Gbps DMLs are differentiated by their ability to achieve state-of-the-art modulation speed and signal quality at high output power and low power consumption. As a result, II-VI's DMLs are preferred over EMLs in 400 GbE and 800 GbE transceivers that use 100 Gbps optical lanes.

08:15 EDT Broadstone Acquisition receives notice from NYSE - Broadstone Acquisition received written notification from NYSE on May 25 that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended March 31 with the SEC, the Company does not comply with the continued listing requirements under Section 802.01E of the Listed Company Manual, which requires NYSE-listed companies to timely file all periodic reports with the SEC. The NYSE informed the Company that the Company has six months from the 10-Q filing due date to file the Form 10-Q. The Notice has no immediate effect on the listing or trading of the Company's securities on the NYSE.

08:10 EDT Viracta Therapeutics begins NAVAL-1 global Phase 2 basket trial for EBV+lymphoma - Viracta Therapeutics announced the initiation of NAVAL-1, a global, multicenter, open-label Phase 2 basket trial for the treatment of relapsed/refractory EBV-positive lymphoma. NAVAL-1 is designed to potentially support multiple new drug application filings across various EBV+ lymphoma subtypes. NAVAL-1 will evaluate nanatinostat in combination with valganciclovir in patients with EBV+ R/R lymphoma and is anticipated to enroll approximately 140 patients at centers in North America, Europe, and Asia-Pacific. The primary endpoint of the trial is objective response rate, with key secondary endpoints including duration of response, survival outcomes, and the safety profile of the combined treatment. Patients with EBV+ relapsed or refractory disease following two or more prior therapies (one or more for extranodal NK/T cell lymphoma) without curative treatment options will be eligible for enrollment.

08:09 EDT Selecta announcer paper on hepatic tolerogenic potential of ImmTOR - Selecta Biosciences announced the peer-reviewed publication of a study investigating the effects of ImmTOR nanoparticles in generating a tolerogenic environment in the liver. The data, published in a Frontiers in Immunology paper titled "Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles," demonstrate that ImmTOR induces a tolerogenic phenotype in all major resident antigen-presenting cell populations in the liver, resulting in modulation of hepatic T cell populations. These findings demonstrate the capability of Selecta's ImmTOR platform in promoting hepatic immune tolerance, providing support for the potential of ImmTOR for the treatment of autoimmune diseases affecting the liver. "Liver specific autoimmune diseases result from the loss of natural immunological tolerance to hepatic autoantigens," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "The data outlined in this publication demonstrate that ImmTOR could effectively enhances the tolerogenic environment of the liver by inducing tolerogenic antigen-presenting cells and was observed to be protective in an acute mouse model of autoimmune hepatitis. These data are of particular relevance to our primary biliary cholangitis program, and we look forward to building on these findings as we advance our first autoimmune program towards the clinic."

08:08 EDT Pembina Pipeline to acquire Inter Pipeline for C$19.45 per share - Pembina Pipeline and Inter Pipeline announced that they have entered into an arrangement agreement for Pembina to acquire all of the issued and outstanding shares of Inter Pipeline in a share-for-share transaction which values Inter Pipeline common shares at approximately C$8.3B, or $19.45 per share, based on the closing price of Pembina's common shares on May 31. The Transaction will create one of the largest energy infrastructure companies in Canada, with a pro forma enterprise value of C$53B and a diversified and integrated asset base that can support and grow an extensive value chain for natural gas, natural gas liquids and crude oil, from wellhead to end user. Furthermore, past and future investments by both companies will help access new demand markets for the Western Canadian Sedimentary Basin, benefitting Pembina, its customers and the provinces of Alberta and British Columbia alike. Under the terms of the Transaction, Inter Pipeline shareholders will receive 0.5 of a share of Pembina for each share of Inter Pipeline that they own. The consideration to be received by Inter Pipeline shareholders is valued at C$19.45 per Inter Pipeline share based on the closing price of Pembina common shares on May 31, which represents a premium of approximately 17.8% to the value implied by the takeover bid announced by Brookfield Infrastructure Corporation. The Transaction is valued at approximately C$15.2B, including the assumption of Inter Pipeline's debt. Pembina and Inter Pipeline shareholders are expected to own 72% and 28% of the combined company, respectively. The combined entity will continue to be led by Pembina's senior executive team. Representation from Inter Pipeline on Pembina's board of directors will be determined prior to closing of the Transaction. The Board of Directors of each of Pembina and Inter Pipeline have unanimously approved the arrangement agreement and support the Transaction. The Transaction is structured through a plan of arrangement under the Business Corporations Act, and is subject to the approval of at least two-thirds of the votes cast by holders of Inter Pipeline shares at a special meeting of Inter Pipeline shareholders. The issuance of Pembina common shares pursuant to the Transaction is subject to the approval by a majority of votes cast by holders of Pembina common shares at a meeting of Pembina shareholders. Details of the Transaction and the required shareholder votes will be included in a joint information circular that Pembina and Inter Pipeline expect to mail to their respective shareholders by late-June, and the special shareholder meetings of both companies are expected to be held in mid-summer 2021. In addition to shareholder approvals, the Transaction is subject to regulatory approvals, as well as the approval of the Court of Queen's Bench of Alberta. The Transaction is expected to close in the fourth quarter.

08:07 EDT Nuwellis awarded three-year contract with Premier - Nuwellis (NUWE) has been awarded a three-year national contract with Premier (PINC). The new Aquapheresis category agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Aquadex SmartFlow, the gentle fluid management technology developed by Nuwellis. The collaboration provides Nuwellis with the opportunity to expand into many of the thousands of hospitals with which Premier holds relationships. The agreement was included in the expedited approval program instituted by Premier to quickly offer COVID-19 innovations to patients.

08:05 EDT Onconova appoints Mark Gelder as CMO - Onconova Therapeutics announced that Mark Gelder, M.D. will be joining Onconova as CMO, effective as of June 14, 2021. He was most recently the CMO of Elevar Therapeutics, where he led the company's clinical development, medical affairs, regulatory affairs, and preclinical teams.

08:04 EDT Neuronetics appoints Todd Cushman as VP, business development - Neuronetics announced that Todd Cushman will join the company as Vice President, Business Development, effective immediately. Mr. Cushman will be responsible for international strategy and Company commercial operations, including contract manufacturing, field service and technical support. Anthony Pui, Vice President, International Commercial Development, will report to Mr. Cushman in his new role. Before joining Neuronetics, he was a founding member of Bioness, Inc., a medical technology company specializing in neurological rehabilitation and implantable products for pain management and held several leadership roles throughout his tenure - including president and CEO from 2013 to 2021.

08:04 EDT Pembina Pipeline to acquire Inter Pipeline in $8.3B share-for-share transaction

08:02 EDT Mitek Systems acquires ID R&D to advance biometric identity fraud protections - Mitek announced that it has acquired ID R&D. Shareholders of ID R&D will be entitled to receive up to $49M in Mitek stock and cash as consideration. "Today's consumers are transacting in a digital-first world, and they expect to trust technology to keep them safe against burgeoning threats. Identity verification has never been more relevant," said Max Carnecchia, CEO Mitek Systems. "Rapid advances in artificial intelligence are enabling novel forms of fraud, which means technologies like those pioneered by ID R&D are critical in this fight." The integration of Mitek and ID R&D simplifies and secures the entire transaction lifecycle for both businesses and consumers. Businesses and financial institutions will have access to one authentication solution to deploy throughout the complete transaction cycle, and can provide consumers with a simple, intuitive approach to fighting fraud. In addition to integrating into the Mitek solution, ID R&D will continue to offer its core biometric components directly to the market. ID R&D will also continue to operate under its brand.

07:59 EDT PyroGenesis appoints Ben Simo as CFO - PyroGenesis Canada announced the appointments of Nannette Ramsey, as an independent director to the Board of Directors and, separately, Ben Simo as CFO of the Company. Ramsey more recently served as the Site Manager and Associate Director of Engineering for Edgewood Chemical Biological Center's site at the Rock Island Arsenal in Illinois. The Company has granted Ramsey stock options to acquire 200,000 common shares of the Company with an exercise price of $6.59 per common share, and which are exercisable over a period of five years. The options are granted in accordance with the Company's stock option plan. The appointment of Ms. Ramsey remains subject to regulatory and exchange approval. Simo brings his extensive experience in corporate finance, operational finance, accounting, taxation and financial reporting to the Company as he will be overseeing the finance/accounting departments while contributing to the execution of the Company's strategic plan. Separately, the Company announces that the Board of Directors has appointed Raymond Chabot Grant Thornton as the Company's new auditor, replacing KPMG, effective May 21st, 2021.

07:54 EDT Plus Products relaunches limited edition gummies for Pride 2021 - Plus Products announced the return of its limited edition Rainbow Sherbet cannabis-infused gummies for Pride 2021. As part of its commitment to acknowledge, elevate and celebrate the intersectionality of race and queer life, PLUS is collaborating with the San Francisco-based Transgender, Gender-Variant & Intersex Justice Project to donate a portion of proceeds from each tin sold to further their mission of ending the human rights abuses committed against Black and Brown TGI people inside of California prisons, jails, detention centers and beyond.

07:53 EDT Mirati Therapeutics, Zai Lab enter collaboration for adagrasib in Greater China - Mirati Therapeutics (MRTX) and Zai Lab (ZLAB) announced the companies have entered into a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China. Under the terms of the agreement, Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China. Zai Lab will support accelerated enrollment in key global, registration-enabling clinical trials of adagrasib in patients with cancer who have a KRASG12C mutation. Mirati has an option to co-commercialize in Greater China and retains full and exclusive rights to adagrasib in all countries outside of Greater China. Mirati will receive a $65M upfront payment, with the potential to receive up to an additional $273M in development, regulatory and sales-based milestone payments. Mirati is also eligible to receive high-teen- to low-twenties-percent tiered royalties based on annual net sales of adagrasib in Greater China.

07:51 EDT FDA approves Paratek's sNDA for NUZYRA to treat CABP - Paratek Pharmaceuticals announced that the U.S. Food and Drug Administration FDA has approved the Company's supplemental New Drug Application, sNDA, for the oral-only dosing regimen of NUZYRA for the treatment of adults with CABP. "The approval of an oral-only dose regimen for NUZYRA in pneumonia represents a significant opportunity to offer clinicians the ability to treat patients in either the outpatient or primary care setting. Treating in this way potentially reduces or eliminates hospitalizations and the associated risk and costs from a hospital stay," said Adam Woodrow, President and Chief Commercial Officer of Paratek. "With the community expansion well under way we will broaden our promotional efforts to include this new dosing option and are particularly excited to bring primary care practitioners a new, safe and effective oral antibiotic in time for the upcoming pneumonia season." Approved by the FDA on October 2, 2018, NUZYRA is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of CABP and acute bacterial skin and skin structure infections. The recently approved oral-only dose for CABP has an initial dose of 300 mg twice on day one and 300 mg once daily thereafter for a total of 7 to 14 days. A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, and atypicals including other drug-resistant strains.

07:48 EDT Celldex abstract for CDX-0159 Phase 1b accepted - Celldex Therapeutics announced that an abstract describing results from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria, ColdU, and symptomatic dermographism, SD, the two most common forms of chronic inducible urticaria, CIndU, has been accepted as a late-breaking electronic Poster Discussion Session (ePDS) at the European Academy of Allergy and Clinical Immunology, EAACI, Annual Congress 2021, being held July 10-12, 2021. The ePDS is chaired and will consist of a pre-recorded presentation followed by questions from session chairs during a dedicated timeslot.

07:44 EDT Immunovant appoints William Macias as CMO - Immunovant (IMVT) also announced the appointment of William Macias, MD PhD, as Chief Medical Officer. He succeeded Rita Jain, M.D., who informed the company of her plans to step down from her position as Chief Medical Officer to pursue another opportunity. Dr. Macias previously served as a Distinguished Medical Fellow and a member of senior management at Eli Lilly (LLY), where he worked for over twenty years.

07:41 EDT BridgeBio gets 'Fast Track' designation for encaleret for ADH1 treatment - BridgeBio Pharma announced that the FDA granted Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia ,ADH1,. The FDA Fast Track designation program is designed to facilitate the development and to expedite the review of new therapies hoping to treat or prevent serious conditions and fill an unmet medical need. BridgeBio announced the Fast Track designation on World Hypoparathyroidism Awareness Day, an annual global awareness and education event designed to spotlight and support people living with ADH1 and other types of hypoparathyroidism.

07:39 EDT Biogen, Bio-Thera announce results from Phase 3 study of BAT1806 - Biogen and Bio-Thera Solutions announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing ACTEMRA/RoACTEMRA. The study met its primary endpoints, demonstrating equivalence to the reference medicine in patients with moderate to severe rheumatoid arthritis inadequately controlled by methotrexate therapy. The primary endpoint in the study was the American College of Rheumatology 20 percent response criteria. ACTEMRA/RoACTEMRA's primary indication is for moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis, systemic juvenile idiopathic arthritis, giant cell arteritis and cytokine release syndrome. Biosimilars are products that demonstrate similar efficacy and safety to the originator's reference product, with the advantage that they can be more affordable for patients and healthcare systems. In 2020 global sales of ACTEMRA were 2.8 billion CHF. Biogen has exclusive regulatory, manufacturing and commercial rights to BAT1806 in all countries excluding China. Biogen and Bio-Thera announced a commercialization and license agreement in April 2021 to develop, manufacture and commercialize BAT1806. As satisfactory results were met, Biogen will make a payment of $30M to Bio-Thera Solutions. Should certain commercial milestones be achieved, Bio-Thera Solutions will be eligible to receive potential milestone payments. Biogen will also pay Bio-Thera Solutions tiered royalties.

07:38 EDT GoldMining initiates preliminary economic assessment on Sao Jorge project - GoldMining announced that it is initiating a preliminary economic assessment, or PEA, on its 100% owned Sao Jorge Gold Project in Para State, Brazil and announces the results of an updated Mineral Resource Estimate, or MRE. Highlights include indicated Mineral Resources of 0.71M ounces gold, or 14.27M tonnes grading 1.55 g/t gold; inferred Mineral Resources of 0.72M ounces gold, or 17.58M tonnes grading 1.27 g/t gold; the MRE utilizes an optimized pit shell to constrain resources, a database of 145 drill holes totaling more than 37,000 metres and uses modernized cost and pricing assumptions including a $1,600/oz gold price; and GoldMining has initiated work on a PEA at Sao Jorge to further evaluate the economic potential of an open-pit operation and advance opportunities to upgrade and expand the current resource base.

07:36 EDT Golden Star announces amendment to sale of of Bogoso-Prestea - Golden Star Resources announces that, on May 31 the Company and its wholly owned subsidiary, Caystar Holdings, entered into an agreement with Future Global Resources, or FGR, and its major shareholder, Blue International Holdings, or BIH, to further amend the share purchase agreement dated July 26, 2020 relating to the sale of Golden Star's 90% interest in the Bogoso-Prestea Gold Mine in Ghana to FGR, as supplemented by a letter agreement dated September 30, 2020, and amended by a first amending agreement dated March 28. The staged payments that form the deferred consideration, as outlined in the Share Purchase Agreement, have been reprofiled to allow time for FGR to complete ongoing financing transactions and the environmental bonding process for Bogoso-Prestea. The deferred consideration payments will now fall due as follows: $15M payment that was due on May 31 will now be payable by no later than July 16; should FGR complete a financing transaction prior to July 16 $5M will be immediately payable to Golden Star with the remaining $10M continuing to fall due on July 16; and an amount of approximately $4.6M will continue to fall due by no later than July 31.

07:35 EDT Silvercorp Metals reports results from 2021 exploration programs at TLP mine - Silvercorp Metals reported results from its 2021 exploration programs at the TLP mine, Ying Mining District, Henan Province, China. "Extensive exploration drilling and tunneling are ongoing at the TLP mine, and all other mines at the Ying Mining District," the company said. From October 1, 2020 to May 31, 2021, 34,546 metres from a total of 196 diamond drill holes, including 161 underground holes and 35 surface holes, were completed at the TLP mine. Assay results for 193 holes have been received, with 108 holes intercepting mineralization. Currently, 13 rigs are drilling at the TLP mine.

07:34 EDT Apyx Medical announces FDA 510k submission for use of renuvion - Apyx Medical announced it has submitted a 510k premarket notification to the Food and Drug Administration, which is intended to obtain a specific clinical indication for the use of Renuvion in dermal resurfacing procedures. "Following the recent completion of our U.S. IDE clinical study evaluating the use of our Renuvion technology in dermal resurfacing procedures, we were pleased to submit our 510k premarket notification for this procedure category on May 28th," said Charlie Goodwin, President and CEO. "This submission is an important milestone that underscores our continued progress in pursuing specific clinical indications to market and sell Renuvion for target procedures in the cosmetic surgery market. I would like to thank our clinical and regulatory teams for their exceptional efforts which has made our recent progress possible, and look forward to the FDA's review of our submission."

07:33 EDT Alkermes jumps 6% to $23.92 after FDA approval of schizophrenia drug

07:32 EDT Mirati and Zai Lab enter into collaboration and license agreement for adagrasib - Mirati Therapeutics (MRTX) and Zai Lab (ZLAB) announced the companies have entered into a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China. Under the terms of the agreement, Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China. Zai Lab will support accelerated enrollment in key global, registration-enabling clinical trials of adagrasib in patients with cancer who have a KRASG12C mutation. Mirati has an option to co-commercialize in Greater China and retains full and exclusive rights to adagrasib in all countries outside of Greater China. Mirati will receive a $65M upfront payment, with the potential to receive up to an additional $273 million in development, regulatory and sales-based milestone payments. Mirati is also eligible to receive high-teen- to low-twenties-percent tiered royalties based on annual net sales of adagrasib in Greater China.

07:32 EDT Sonim names Robert Tirva as COO; CEO Tom Wilkinson to depart - Sonim Technologies announced that Robert Tirva, currently serving as CFO, will be promoted to President and COO. He will report directly to the Board of Directors and work closely with the Strategic Alternatives and Operating Committee. The company also announced that Tom Wilkinson, who has served as CEO since October 2019, will depart the company.

07:26 EDT Silvercorp Metals reports results from 2021 exploration programs at TLP mine - Silvercorp Metals is pleased to report results from its 2021 exploration programs at the TLP mine, Ying Mining District, Henan Province, China. Extensive exploration drilling and tunneling are ongoing at the TLP mine, and all other mines at the Ying Mining District. From October 1, 2020 to May 31, 2021, 34,546 metres from a total of 196 diamond drill holes, including 161 underground holes and 35 surface holes, were completed at the TLP mine. Assay results for 193 holes have been received, with 108 holes intercepting mineralization. Currently, 13 rigs are drilling at the TLP mine. The diamond drilling programs at the TLP mine targeted resource blocks of known silver-lead-zinc veins in the production areas that were missed by limited prior drilling and drifting tunnels, as a result of changes in the dip and pinch-swelling of the pay-zones in the veins. Since access tunnels are already in place, any discovered high-grade blocks can quickly be converted to reserves and mined. The high-grade intercepts for this period are associated with parallel veins T15W, T15W1, T15W2, and T15W3. Other veins include T16E, T2, T2W, T3, T16E, T11, T1, T1a, T22, T23, T24, T33 and T35E1. Highlight of high-grade intercepts in the TLP production area: Hole ZKG6AT15W304 intersected a 2.49 m interval of vein T15W2 grading 3,911 grams per tonne silver, 6.22% lead, 2.11% zinc, 0.08 g/t gold and 0.55% copper at the 808 m elevation, which includes a 0.97 m interval grading 9,901 g/t Ag, 15.30% Pb, 5.27% Zn, 0.19 g/t Au, and 1.39% Cu; Hole ZKG6AT15W305 intersected a 1.62 m interval of vein T15W3 grading 1,556 g/t Ag, 15.27% Pb, 0.24% Zn, 0.10 g/t Au, and 0.23% Cu at the 813 m elevation; Hole ZKT3AT1W101 intersected a 4.00 m interval of vein T23 grading 771 g/t Ag, 11.68% Pb, 0.23% Zn, 0.08 g/t Au, and 0.11% Cu at the 854 m elevation; Hole ZKT7T3E02 intersected an 8.44 m interval of vein T3E grading 523 g/t Ag, 5.10% Pb, 0.36% Zn, 0.11 g/t Au, and 0.13% Cu at the 1,086 m elevation, which includes a 4.20 m interval grading 1,036 g/t Ag, 9.96% Pb, 0.67% Zn, 0.18 g/t Au, and 0.24% Cu at the 1,087 m elevation; Hole ZKT23J001 intersected a 0.89 m interval of vein T2 grading 1,283 g/t Ag, 8.60% Pb, 2.30% Zn, 4.22 g/t Au, and 1.30% Cu at the 676 m elevation; Hole ZKTDB39T103 intersected a 2.90 m interval of vein T3 grading 1,115 g/t Ag, 1.20% Pb, 0.09% Zn, 0.08 g/t Au, and 0.11% Cu at the 818 m elevation; Hole ZKTDB05Y03_1 intersected a 0.52 m interval of vein T35E1 grading 2,086 g/t Ag, 5.79% Pb, 0.62% Zn, 0.05 g/t Au, and 0.35% Cu at the 914 m elevation; and Hole ZKTDB43T302 intersected a 1.04 m interval of vein T3E grading 520 g/t Ag, 1.25% Pb, 0.05% Zn, 4.36 g/t Au, and 0.11% Cu at the 730 m elevation. Exploratory surface drilling in the east and south sides of the resource area in the TLP mine discovered high-grade silver-lead-zinc mineralization at higher elevations. These intercepts of veins T39E2, T17 and T38 are expected to expand the resources in these areas. Hole ZKG4T15W113 intersected a 3.96 m interval of vein T15W1 grading 1,086 g/t Ag, 0.93% Pb, 0.19% Zn, 0.19 g/t Au, and 0.15% Cu at the 672 m elevation; Hole ZKTDB20T1701 intersected a 3.48 m interval from 170.40 m to 173.88 m of vein T17, grading 675 g/t Ag, 0.92% Pb, 0.43% Zn, 0.01 g/t Au, and 0.15% Cu at the 893 m elevation, which includes a 0.78 m interval from 171.26 m to 172.04 m grading 2,206 g/t Ag, 1.44% Pb, 0.71% Zn, 0.02 g/t Au, and 0.40% Cu at the 892 m elevation; Hole ZKTDB27AT39E201 intersected a 0.81 m interval from 99.41 m to 100.22 m of vein T39E2 grading 1,705 g/t Ag, 1.3% Pb, 0.35% Zn, 0.02% Au, and 0.06% Cu at the 803 m elevation; and Hole ZKTDB25AT39E201 intersected a 1.71 m interval from 169.08 m to 170.79 m of vein T39E2 grading 456 g/t Ag, 16.16% Pb, 2.55% Zn, 0.01% Au, and 0.11% Cu at the 785 m elevation. In addition to the drilling program, 4,526 m of exploration drift tunneling were developed at the TLP mine during this period. Highlights of selected mineralized zones exposed in the drift tunnels: Drift Tunnel PD890-T16E-890-2NYM exposed mineralization 85 m long and 0.64 m wide grading 721 g/t Ag, 2.62% Pb and 0.72% Zn within vein T16E on the 893 m level; Drift Tunnel PD820-T22E-700-16NYM exposed mineralization 30 m long and 0.81 m wide grading 692 g/t Ag, 3.43% Pb and 1.05% Zn within vein T22E on the 704 m level; Drift Tunnel PD960-T33-990-13NYM exposed mineralization 20m long and 0.44 m wide grading 1,841 g/t Ag, 1.81% Pb and 1.31% Zn within vein T33 on the 960m level; and Drift Tunnel PD846-T11E-846-10SYM exposed mineralization 110m long and 0.68 m wide grading 427 g/t Ag, 2.26% Pb and 0.44% Zn within vein T11E on the 858 m level.

07:26 EDT Nuvation Bio appoints David Hanley as Chief Technical Operations Officer - Nuvation Bio announced the appointment of David C. Hanley, as Chief Technical Operations Officer, joining the Company's executive management team. In his new role, Hanley will oversee all early- and late-stage pharmaceutical development and operations, including supply chain, product development and manufacturing efforts, and work closely on commercial planning with Quality, Regulatory Affairs, Clinical Development and Clinical Operations teams. Hanley brings 20 years of pharmaceutical industry experience driving strategy for technical operations and chemistry manufacturing and controls (CMC), including virtual networks, for drug development, manufacturing and distribution in the U.S. and worldwide. He holds diverse disease expertise, including oncology, central nervous system and autoimmune, and product types, including biologics, small molecule therapies, cell therapies and synthetic peptide products. Hanley most recently served as Senior Vice President and Head of Global Pharmaceutical Development and Operations at BioXcel Therapeutics, where he led strategy and execution for CMC development, end-to-end supply chain and external supply manufacturing.

07:21 EDT Alnylam completes enrollment in APOLLO-B phase 3 study of patisiran - Alnylam Pharmaceuticals announced that it has achieved full patient enrollment in its APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of cardiomyopathy in patients with transthyretin-mediated, or ATTR, amyloidosis. Enrollment was completed with over 300 ATTR amyloidosis patients across 90 sites in more than 20 countries. APOLLO-B is the industry's furthest progressed randomized, double-blind, placebo-controlled study of a TTR silencer investigational medicine for the treatment of cardiomyopathy in hATTR and wtATTR amyloidosis patients. Patisiran is the established name for ONPATTRO, which is approved in the United States, Canada and Japan for the treatment of the polyneuropathy of hATTR amyloidosis in adults and in the European Union, Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy. Rena Denoncourt, Vice President, TTR Franchise Lead said, "We look forward to announcing topline APOLLO-B results in mid-2022 and are excited about the potential of patisiran to treat multiple manifestations of this rapidly progressive disease and further advance our aspiration to build the industry leading franchise of RNAi therapeutics for the treatment of ATTR amyloidosis."

07:21 EDT Tesla's Musk attributes higher vehicle prices to supply chain price pressure - In a Tweet responding to complaints about reduced features and higher prices for Tesla vehicles, CEO Elon Musk stated: "Prices increasing due to major supply chain price pressure industry-wide. Raw materials especially." Reference Link

07:18 EDT BridgeBio's QED therapeutics, Helsinn Group announce FDA approval of truseltiq - BridgeBio Pharma, through its affiliate QED Therapeutics, and Helsinn Group announced that the US Food and Drug Administration has approved truseltiq under the accelerated approval program for the treatment of patients with previously-treated locally advanced or metastatic cholangiocarcinoma, or CCA, harboring an FGFR2 fusion or rearrangement. truseltiq is an orally administered, ATP-competitive, tyrosine kinase inhibitor of FGFR. In the pivotal trial of patients with advanced, unresectable CCA, an aggressive malignancy with poor prognosis, truseltiq led to cases of tumor shrinkage. The approval of TRUSELTIQ is based on a Phase 2 clinical study in which 108 patients who had undergone at least one prior treatment for advanced CCA received 125 mg of truseltiq daily for 21 days of 28-day cycles. Of these patients, 107 had Stage IV CCA. All patients had received at least 1 prior line of systemic therapy. The study's primary endpoint demonstrated a confirmed objective response rate of 23%. The study also showed a median duration of response of 5.0 months. Additional marketing applications for infigratinib are currently under review in Australia and Canada under Project Orbis, an initiative of the FDA's Oncology Center of Excellence that allows for concurrent submission and review of oncology drugs among participating international regulatory agencies. BridgeBio and Helsinn Group's affiliate, Helsinn Therapeutics, will be jointly responsible for commercialization activities in the U.S. and will share U.S. profits and losses on an equal basis. Helsinn Group will have exclusive commercialization rights on infigratinib outside of the U.S., excluding China, Hong Kong and Macau. BridgeBio will be eligible for tiered royalties as a percentage of adjusted net sales, and payments totaling up to approximately $2.45B in the aggregate. Helsinn Group will fund the majority of ongoing and future research and development related to infigratinib in oncology. BridgeBio and Helsinn Group entered into a global collaboration and licensing agreement in March 2021. BridgeBio previously entered a strategic collaboration with LianBio for development and commercialization of infigratinib in oncology indications in China, Hong Kong and Macau.

07:17 EDT Corbus Pharmaceuticals licenses two integrin targeting mAbs - Corbus Pharmaceutical sannounced licensing deals for two new monoclonal antibodies, mAbs, CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor beta,TGFbeta. This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus' immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer. With these additions, Corbus expects to have four compounds other than lenabasum in Phase 1 testing in 2022. Targeting integrins to inhibit TGFbeta activation. TGFbeta is a multifunctional cytokine involved in many cellular processes, including cell growth and differentiation, immune responses, wound healing, and tissue repair. TGFbeta plays a key role in fibrosis and also promotes cancer growth and metastasis via its effects in the tumor microenvironment. The integrins alphavbeta6 and alphavbeta8 are expressed by cancer cells, and alphavbeta6 is also expressed on epithelial cells in fibrotic diseases. These integrins enable TGFbeta to exert its biologic effects by releasing it from its latent complex. The goal of blocking

07:15 EDT Comscore signs renewal agreement with Minute Media - Comscore announced it has signed a renewal agreement with Minute Media for the use of Comscore's granular digital audience measurement solutions. The multi-year agreement, which sees Minute Media continuing to use Comscore Media Metrix Multi-Platform and Video Metrix Multi-Platform for U.S. and Hispanic audiences, will enhance Minute Media's current audience measurement and ad planning functionalities.

07:14 EDT Nabriva Therapeutics reports inducement grants under Nasdaq listing rule - Nabriva Therapeutics announced that it has granted non-statutory stock options to purchase an aggregate of 6,000 ordinary shares of Nabriva Therapeutics as an inducement to two newly-hired employees. These grants were awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation. The stock options were granted effective May 28, 2021 with an exercise price of $1.38 per share, which is equal to the closing price of Nabriva Therapeutics's ordinary shares on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 25% of the original number of shares vesting on the annual anniversary of the grant date until fully vested, subject to the employee's continued service with the Company through the applicable vesting dates. The stock option awards were approved by Nabriva Therapeutics' Compensation Committee and were granted as an inducement material to each employee's acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options is subject to the terms and conditions of a stock option agreement covering the grant and Nabriva Therapeutics' 2021 Inducement Share Incentive Plan.

07:14 EDT Sutro Biopharma receives milestone payment from Merck KGaA - Sutro Biopharma (STRO) announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA (MKGAY), Darmstadt, Germany, related to a patient enrollment achievement in the Phase 1 dose escalation and expansion study of M1231 in adult patients with metastatic solid tumors, including non-small cell lung cancer, or NSCLC, and esophageal squamous cell carcinoma. M1231 is an investigational bispecific antibody-drug conjugate, or ADC, targeting MUC1-EGFR. M1231 was generated using Sutro's XpressCF and Sutro's XpressCF+ cell-free protein synthesis and conjugation technologies and includes a Sutro proprietary linker-warhead.

07:13 EDT Sutro Biopharma receives milestone payment from Merck KGaA - Sutro Biopharma (STRO) announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, related to a patient enrollment achievement in the Phase 1 dose escalation and expansion study of M1231 in adult patients with metastatic solid tumors, including non-small cell lung cancer, or NSCLC, and esophageal squamous cell carcinoma. M1231 is an investigational bispecific antibody-drug conjugate, or ADC, targeting MUC1-EGFR. M1231 was generated using Sutro's XpressCF and Sutro's XpressCF+ cell-free protein synthesis and conjugation technologies and includes a Sutro proprietary linker-warhead.

07:11 EDT Bespoke Capital shareholders approve merger with Vintage Wine Estates - Bespoke Capital Acquisition announced that BCAC's shareholders voted to approve its proposed merger with Vintage Wine Estates at its shareholder meeting held on May 28, 2021. The domestication of BCAC from British Columbia to Nevada was also approved. On February 4, 2021, BCAC announced a definitive agreement for a business combination with Vintage Wine Estates. Upon closing, the combined company will be named Vintage Wine Estates, Inc. Its common stock will remain listed on the Nasdaq Global Market under the new ticker symbol "VWE" and on the TSX under the symbol "VWE.U". The warrants will remain listed on the TSX under "VWE.WT.U". BCAC also announced that VWE's shareholders have approved the proposed merger. The closing of BCAC's business combination with VWE is expected to occur on or about June 7, 2021.

07:11 EDT Cloudera reports Q1 subscription revenue $200.7M, up 7% y/y - Annualized Recurring Revenue grew 12% year-over-year to $805M. Operating cash flow for the first quarter of fiscal 2022 was $162.2M, compared to $68.4M for the first quarter of fiscal 2021. Non-GAAP subscription gross margin for the quarter was 91%, up from 88% in the first quarter of fiscal 2021.

07:10 EDT Passage Bio appoints Derrell Porter to board of directors - Passage Bio announced the election of Derrell Porter, M.D., to its board of directors and his appointment to the Audit Committee, effective as of May 27, 2021, the date of Passage Bio's Annual Meeting of Stockholders. Dr. Porter is founder and CEO of Cellevolve Bio, a cell therapy company focused on transforming investigational CNS, oncology and transplant therapies into commercial products.

07:09 EDT PGS, Ion Geophysical complete Shell Egypt survey - ION Geophysical Corporation (IO) and PGS (PGS) announced the completion of a survey offshore Egypt acquired on behalf of Shell (RDS.A) with an Extended Long Offset design in combination with ION's Gemini source technology. This is the last in a string of PGS programs successfully acquired in the Mediterranean starting in July 2020, and the first proprietary deployment of ION's extended frequency source. The Ramform Tethys towed a wide multi-sensor GeoStreamer configuration, while the Ramform Sovereign towed ION's extended frequency source, designed to help capture richer low frequencies to improve subsurface characterization while limiting higher frequencies to a more ecologically-friendly range. All three companies are aligned in their dedication to sustainable business practices that minimize the environmental impact of operations.

07:08 EDT MSCI appoints Rajat Taneja to board of directors - MSCI (MSCI) announced that Rajat Taneja, President of Technology for Visa (V), has been appointed to serve as an independent director on MSCI's board of directors, effective June 1, 2021. Taneja will serve as a member of the Audit Committee of the board. Following the appointment of Taneja, the board will be comprised of 10 directors.

07:07 EDT Prospect Capital says preferred stock offering cumulative issuances exceed $100M - Prospect Capital Corporation announced that Prospect's preferred stock offering of Series A1, M1, M2, and A2 cumulatively has issued $105.9 million in aggregate preference amount since the initial closing in the quarter ending December 31, 2020. The Preferred Stock has a stated annual dividend rate of 5.5%, paid monthly and ranks senior to over $3.6 billion of Prospect's common stock. The Preferred Stock is perpetual and convertible into our publicly traded common stock at the preferred investor's discretion.

07:06 EDT Heritage Cannabis to acquire Bloom Brands for $15M in all share transaction - Heritage Cannabis announced it has entered into a non-binding letter of intent to purchase all of the issued and outstanding common shares of California based Capna Intellectual/dba Bloom Brands in an all share transaction. Under the terms of the Agreement, Bloom will receive approximately $15M of Heritage common shares in two tranches. The first tranche of $7.5M will be at a deemed value of CA 14c per Heritage share, followed by a second tranche of shares six months after closing at a deemed value of either the greater of CA 16c or a 15% discount to the 15-day VWAP. The agreement also includes potential milestone payments of up to an additional $17M of Heritage common shares contingent upon Bloom achieving certain financial targets over a twelve-month period. All shares issued as part of the agreement will be subject to lock-up provisions and applicable statutory hold periods. The transaction is expected to close by the end of July and is subject to customary closing conditions and applicable third party and regulatory approvals. There can be no assurance that the transaction will be completed on the terms set out herein or at all.

07:05 EDT Green Thumb Industries closes on acquisition of Liberty Compassion - Green Thumb Industries announced that it has closed on an acquisition of Liberty Compassion, a Massachusetts-based medical cannabis cultivator and retailer. The acquisition adds cultivation and production capacity and two operating medical cannabis dispensaries located in Boston and West Springfield. With the acquisition, Green Thumb now has two operational cultivation and production facilities in Massachusetts to serve the growing consumer demand for cannabis. Green Thumb's branded products, including Dogwalkers brand pre-roll joints; Doctor Solomon's medical-grade drops, lotions and balms; incredibles gummies, chocolates and tarts; and Rythm premium flower and vapes, are produced in the Commonwealth and available at licensed cannabis dispensaries across Massachusetts. The two Affinity cannabis stores join Green Thumb's Rise Amherst location, which serves medical patients and recreational customers.

07:04 EDT Stock Yards Bancorp completes acquisition of Kentucky Bancshares - Stock Yards Bancorp announced that it has completed its previously announced acquisition of Kentucky Bancshares, Inc. Kentucky Bancshares, headquartered in Paris, Kentucky, is the holding company for Kentucky Bank, which operates 19 branches in 11 communities throughout central and eastern Kentucky, including the Lexington, Kentucky metropolitan statistical area and contiguous counties.

07:03 EDT Clarus to acquire Rhino-Rack for $198M - Clarus Corporation announced it has entered into a definitive agreement to acquire Australia-based Rhino-Rack, a manufacturer and distributor of highly-engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, and accessories, for an aggregate purchase price of approximately $198M. Rhino-Rack will continue to operate independently as a wholly-owned indirect subsidiary of Clarus and will constitute a third reporting segment associated with mobile solutions for outdoor adventure. The purchase consideration is comprised of $150M cash and approximately 2.3 million shares of Clarus common stock calculated pursuant to the terms of the purchase agreement. Richard Cropley, Rhino-Rack's founder and Managing Director, is anticipated to be a top five shareholder of Clarus following the completion of the transaction. In addition, an earn-out of $8M in cash is payable on July 31, 2022, contingent on the achievement of a specified revenue target. The Company expects the cash consideration to be financed through the upsizing of the Company's existing credit facility led by J.P. Morgan. The acquisition of Rhino-Rack is expected to be immediately accretive to Clarus following closing. Headquartered in Sydney, Australia and founded in 1992 by Mr. Cropley, Rhino-Rack is an iconic brand that embodies the Clarus' Super Fan ethos. Rhino-Rack has leading market share for its core products in Australia and New Zealand with a growing presence globally, particularly in the U.S., and is best known for its superior "north / south" roof rack designs with best-in-class solutions that "make space for adventure." Customers rely on Rhino-Rack to transform their vehicles for work, play, or anything in between. Rhino-Rack has well-established routes to market through a combination of long-standing distributors, retail relationships, OEM partners, third-party e-commerce sites and growing direct-to-consumer presence. For the trailing twelve-month period ended March 31, 2021, Rhino-Rack generated approximately $90M in net sales and approximately $16.7M of Adjusted EBITDA. Approximately 80% of Rhino-Rack's sales came from Australia and New Zealand, and 20% from North America. The transaction is expected to close in July 2021, subject to customary closing conditions as well as certain regulatory approvals in New Zealand. Following the closing of the transaction, the Rhino-Rack management team will continue to run the business from Rhino-Rack's headquarters in Sydney, Australia. Clarus expects to provide additional information on the Rhino-Rack transaction in connection with its second quarter conference call expected to be held in August 2021.

06:59 EDT Lannett announces FDA acceptance of ANDA for generic Advair Diskus - Lannett Company (LCI) announced the U.S. Food and Drug Administration has accepted the Abbreviated New Drug Application for Fluticasone Propionate and Salmeterol inhalation powder, which was submitted by Lannett on behalf of its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The FDA assigned a Generic Drug User Fee Act of 2017 goal date for this priority original ANDA of January 31, 2022. The product is the generic equivalent of ADVAIR DISKUS of GlaxoSmithKline (GSK). Total U.S. sales of the product, according to IQVIA (IQV), were approximately $3 billion for the 12 months ending April 2021, although actual generic market values are expected to be lower. As previously announced, Lannett entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Advair Diskus of Respirent. Under the agreement, Lannett will commence U.S. distribution of the product after FDA approval and receive a portion of the net profits once it commences distribution of the product. The companies recently extended the term of the agreement to 12 years post commencement of distribution.

06:55 EDT Alkermes trading halted, news pending

06:51 EDT Northern Dynasty reports USACE completion of AR for Pebble Project appeal - Northern Dynasty Minerals reports that the US Army Corps of Engineers has completed the 'administrative record' that will serve as the basis for its official review of the negative Record of Decision issued for Alaska's Pebble Project last fall. The USACE completed the AR and provided a copy to Northern Dynasty's 100%-owned, U.S.-based subsidiary Pebble Limited Partnership last week. The Pebble Partnership and its legal counsel are currently reviewing the voluminous record for completeness and relevance to the USACE's permitting decision, and its sufficiency to support a fair, transparent and efficient review. The Pebble Partnership also recently learned the USACE is naming a new Review Officer to lead the Pebble Project appeal. Once in place, the Company expects the new RO to set a detailed timeline for the administrative appeal process, including scheduling a potential site visit and appeal conference.

06:48 EDT Sanofi, Merck announce U.S. availabity of pediatric combination vaccine - Vaxelis developed as part of a partnership between Sanofi Pasteur (SNY) and Merck (MRK) is now available in the U.S. Vaxelis is a hexavalent (combination vaccine available in the U.S. Vaxelis is a vaccine given to protect your child from getting diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B. Vaxelis is given to children from 6 weeks through 4 years of age and is given as 3 shots, one at 2 months, one at 4 months and one at 6 months of age. On February 11, 2021, the U.S. Centers for Disease Control and Prevention's Advisory Committee included Vaxelis as a combination vaccine option in the CDC's recommended Child and Adolescent Immunization Schedule. Vaxelis will be widely available in the U.S. through traditional public and private channels, including directly from Sanofi Pasteur via vaccineshoppe.com.

06:40 EDT Schwazze to acquire Southern Colorado Growers for $11.3M - Schwazze announced signed definitive documents to acquire the assets of Southern Colorado Growers in Huerfano County, Colorado. The proposed transaction includes 34 acres of land with outdoor cultivation capacity, as well as indoor, greenhouse, and hoop house cultivation facilities and equipment. This planned purchase continues Schwazze's expansion in Colorado and, is the company's first major move into cultivation, which will provide high-end, premium cannabis directly to its Star Buds dispensaries and significant production of biomass for its PurpleBee's extraction and manufacturing facility. PurpleBee's is Colorado's largest supplier of wholesale distillate for the CPG market, providing quality distillate to leading vaporizer, concentrates and edibles companies. The consideration for the proposed acquisition is $6.8M for the business and $4.5M for the real estate and farm assets. Total consideration of $11.3M will be paid as $5.9M of cash at closing and $5.4M in Schwazze common stock at closing. After closing, Schwazze has major expansion plans for SCG which includes the buildout of additional hoop house facilities over the next four quarters. SCG produces premium flower with approximately 30 strains and has won multiple Connoisseur Cup awards for select strains in 2020. The acquisition is expected to close in Q3 2021, subject to closing conditions and covenants customary for this type of transaction, including, without limitation, obtaining MED and local licensing approval.

06:38 EDT Immunic appoints Inderpal Singh as general counsel - Immunic (IMUX) announced the appointment of Inderpal Singh as General Counsel. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management team of Immunic. Mr. Singh joins Immunic from Sandoz International (NVS), where he served as the Global Legal Head of Biopharma since January 2018.

06:36 EDT Cloudera jumps about 25% above $16 after confirming private equity acquisition

06:32 EDT Lineage Cell Therapeutics annonces new patients with retinal tissue restoration - Lineage Cell Therapeutics announced that restoration of retinal tissue was observed in two additional patients enrolled in the Company's Phase 1/2a study of its lead product candidate, OpRegen. OpRegen is an allogeneic retinal pigment epithelium, or RPE, cell transplant therapy in development for the treatment of age-related macular degeneration, or AMD, with geographic atrophy, or GA, or dry AMD. These new findings occurred in two of the three Cohort 4 patients treated in November of 2020, where surgeons successfully covered the majority of the area of atrophy with a suspension of OpRegen cells. Outer retinal layer restoration, which was observed using clinical high-resolution Optical Coherence Tomography, or OCT, was evidenced by the presence of new areas of RPE monolayer with overlying ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment. These findings suggest integration of the new RPE cells with functional photoreceptors in areas that previously showed no presence of any of these cells. These effects were most prominent in the transitional areas around the primary area of GA. In addition to positive anatomical changes, all three patients' visual acuity increased above baseline levels within 6 months post-transplant. The totality of these findings supports the view that atrophic AMD is not an irreversible, degenerative condition and that some portion of diseased retinal tissue may be recoverable. In connection with these findings, Lineage has filed a Patent Cooperation Treaty patent application which describes restoration of the anatomy and/or functionality of diseased retinas.

06:25 EDT Macau reports May casino revenue up 492.2% to 10.445B patacas - Macau's gaming bureau reported May gross revenue from games of fortune in the region increased 492.2% year-over-year to 10.445B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

06:20 EDT Cloudera confirms deal to be acquired by CD&R, KKR; transaction valued at $5.3B

06:16 EDT Accenture enters agreement to acquire Nell'Armonia, terms not disclosed - Accenture has entered into an agreement to acquire Nell'Armonia, a consulting and technology company specialized in enterprise performance management solutions, headquartered in Paris, France. Financial terms of the transaction are not being disclosed.

06:14 EDT Tiga Acquisition receives not in compliance letter from NYSE - Tiga Acquisition announced that it has received a notice from the NYSE indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31 with the SEC on or prior to the due date thereof or by the extended filing due date provided by Rule 12b-25. The NYSE informed the Company that, under NYSE rules, the Company will have six months from May 24 to file the Q1 2021 Form 10-Q with the SEC. The Company can regain compliance with the NYSE listing standards at any time prior to that date by filing its Q1 2021 Form 10-Q. The Company has concluded that based on the SEC Staff Statement, its warrants and forward purchase agreement should be classified as liabilities measured at fair value, with subsequent changes in fair value recorded in the Company's Statement of Operations at each reporting period. The notice from the NYSE has no immediate effect on the listing of the Company's securities on NYSE and indicates that the company has until November 24, 2021 to regain compliance. The Company expects to file the Q1 2021 Form 10-Q well ahead of this deadline and regain compliance.

06:11 EDT Aurora Mobile announces partnership with Yunji - Aurora Mobile (JG) announced that it has entered into a partnership agreement with Zhejiang Jixiang E-Commerce (YJ), or Yunji, to jointly promote intelligent marketing, digital operations and the development of membership-based e-commerce. Yunji is a leading Chinese membership-based social e-commerce platform offering high-quality products at attractive prices across a wide variety of categories including mobile phones and digital products, beauty and personal care, maternal and childcare products, fresh produce and more. On May 3, 2019, Yunji was listed on Nasdaq and became the first Chinese membership-based e-commerce firm to be listed on a U.S. stock exchange.

06:09 EDT Curo Group subsidiary's financing platform selected by LFL Group - Flexiti Financial announced that LFL Group, Canada's largest home furnishings retailer, has chosen Flexiti's omni-channel customer financing platform for all of LFL's retail banners. Since 2018, the FlexitiCard has been accepted at The Brick stores while LFL customers and all Flexiti cardholders have been able to apply and buy online at thebrick.com and leons.ca since 2019. Through this 10-year agreement, which commences in July 2021, Flexiti broadens its relationship with LFL, becoming the exclusive provider of point-of-sale financing for LFL's customers, in-store and online at all LFL retail banners, including Leon's, leons.ca, The Brick, thebrick.com, Appliance Canada, The Brick Mattress Store, Midnorthern Appliance, and Furniture.ca. All LFL banners will begin issuing FlexitiCards at more than 300 stores across Canada over the coming months. This relationship represents over $800M in annual LFL customer sales which will be financed by Flexiti. Flexiti is a wholly-owned subsidiary of CURO Group Holdings

06:07 EDT High Tide begins sales at two Canna Cabana stores in Alberta - High Tide announced that its Alberta-based Canna Cabana retail stores located at 7400 Macleod Trail SE, Unit #2 in Calgary, and 4806 50 Avenue in Vegreville, have begun selling recreational cannabis products for adult use. These openings bring High Tide's total branded retail locations selling recreational cannabis products and consumption accessories across Canada to 87.

06:06 EDT RingCentral announces partnership with Deutsche Telekom - RingCentral (RNG) announced a partnership with Deutsche Telekom (DTEGY) to transform business communications for customers of all sizes. With Deutsche Telekom's extensive network presence and RingCentral's deep Unified Communications as a Service and Contact Center as a Service capabilities, the partnership will deliver mobility-centric, flexible, easy to use, and secure cloud communication solutions. This will bring the benefits of next-generation communications and collaboration capabilities to companies of every size. As a first step, the partnership will offer Deutsche Telekom's customers a co-branded version of RingCentral Video as a lead stand-alone video solution, which delivers reliable, secure, open, video meetings and team messaging based on RingCentral's leading Message Video Phone platform. Deutsche Telekom will introduce the new solution to customers in the second half of 2021.

06:04 EDT uCloudlink enters partnership with Lions Den Rental Corp. - UCLOUDLINK GROUP has inked a partnership with Lions Den Rental Corp, a global Internet services provider in the United Kingdom. With an expanding footprint in Europe, this agreement supports uCloudlink's ongoing efforts to broaden its business presence across the region and bring high-quality, innovative hyper-connectivity solutions to more users worldwide. Under the agreement, Lions Den will help uCloudlink develop mobile broadband business opportunities in Europe. Lions Den will be responsible for the advertising and promotion of uCloudlink's products and data connectivity services in the U.K., while uCloudlink will support Lions Den with after-sales services for its products.

06:03 EDT Akebia, Otsuka announce FDA acceptance for filing of vadadustat NDA - Akebia Therapeutics (AKBA) and its collaborator, Otsuka Pharmaceutical (OTSKY) announced that the U.S. Food and Drug Administration accepted for filing the New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis. The FDA has assigned the application standard review and a Prescription Drug User Fee Act target action date of March 29, 2022. The FDA also indicated that they are not currently planning to hold an Advisory Committee meeting to discuss the application. Akebia and Otsuka are collaborating on the development and commercialization of vadadustat in the U.S., Europe, China, Russia, Canada, Australia, the Middle East, and certain other territories. In addition, Otsuka is working with Akebia to prepare a Marketing Authorization Application for vadadustat for submission to the European Medicines Agency expected this year.

06:02 EDT Baker Hughes deploys its remote operation technology across Aramco's operations - Baker Hughes announced it has deployed its remote operations digital technology across Aramco's drilling operations, encompassing 200+ sites, the largest deployment of its kind in Baker Hughes' history. Building upon Aramco's existing data management infrastructure and capabilities, this project provides the company with a single solution that covers data aggregation from the edge; real-time, unified data streaming and visualization; data management; software development services; rig-site digital engineers; and monitoring personnel. The project supports Aramco's ongoing efforts to further drive digital opportunities and initiatives and to enhance operating performance and reduce emissions.

05:53 EDT KKR and TIGA Investments to acquire The Executive Centre - The Executive Centre, KKR and TIGA Investments announced the signing of definitive agreements under which a consortium led by KKR and TIGA Investments will acquire TEC. The Executive Centre is a provider of premium flexible office space solutions in markets including Greater China, North Asia, Southeast Asia, Australia, India, Sri Lanka, and the Middle East. The company has expanded rapidly across Asia Pacific since it was founded in 1994, fueled by steady demand for premium workspace in prime, central locations from its client base of leading MNCs. It now serves more than 32,000 members across over 150 centers in 32 cities and 14 markets, including Greater China, Japan, South Korea, Southeast Asia, Australia, India, Sri Lanka, and the Middle East, with an annual turnover in excess of $237M. The Executive Centre's offerings include high-quality enterprise solutions, premium private offices, coworking and virtual spaces, each equipped with meeting & event facilities, and a broad range of full IT support and corporate concierge services. As part of the transaction, funds advised by HPEF Capital Partners and CVC Capital Partners will exit their investments in the company. Members of TEC's management team will continue to own shares in the company.

05:51 EDT KKR invests in EQuest - EQuest Education Group, an educational services provider in Vietnam, and KKR announced that KKR has invested in EQuest. The investment will be used to support EQuest's expansion and advance its mission to provide students in Vietnam with affordable access to world-class education.